

LIST OF CONTENTS

NUMBER 1

<i>International Cancer News</i>		1
<i>Announcement</i>		
	Paediatric Update Series	7
	<i>J. Prichard, H.-J. Senn and D. Purves</i>	
<i>Editorials</i>		
	Childhood acute lymphoblastic leukaemia	8
	<i>G. Henze</i>	
	Incidence and treatment of ductal carcinoma <i>in situ</i> of the breast	10
	<i>M.J. Silverstein</i>	
<i>Current Controversies in Cancer</i>		
	Is abdomino-pelvic radiation therapy the optimal treatment for completely resected stage I and II high risk ovarian cancer?	12
	<i>Pro: A. Fyles</i>	
	<i>Contra: G. Bolis, C. Ferraris and F. Parazzini</i>	
	<i>Arbiter: M. Bolla</i>	
<i>Special Paper</i>		
	Quality of life assessment in clinical trials—guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience	20
	<i>P.M. Fayers, P. Hopwood, A. Harvey, D.J. Girling, D. Machin and R. Stephens on behalf of the MRC Cancer Trials Office</i>	
<i>Review</i>		
	Do oncologists have an increasing interest in the quality of life of their patients?	29
	A literature review of the last 15 years	
	<i>L.M. Batel-Copel, A.B. Kornblith, P.C. Batel and J.C. Holland</i>	
<i>Meeting Highlight</i>		
	International update meeting for paediatric haematology and oncology, Edinburgh, May 1996	33
	<i>T. Eden on behalf of Organising Committee: T. Eden, I. Hann, A. Thomas and H. Wallace</i>	
<i>Clinical Oncology</i>		
	Ductal carcinoma <i>in situ</i> of the male breast. Analysis of 31 cases	35
	<i>B. Cutuli, J.M. Dillhurydy, B. De Lafontan, J. Berlie, M. Lacroze, F. Lesaunier, Y. Graic, J. Tortochaux, M. Resbeut, T. Lesimple, E. Gamelin, F. Campana, M. Reme-Saumon, V. Moncho-Bernier, J.C. Guilliere, C. Marchal, G. De Gislain, T.D. N'Guyen, E. Teissier and M. Velten</i>	

	p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular <i>in situ</i> carcinomas of the breast	39
	<i>M. Rudas, R. Neumayer, M.F.X. Gnant, M. Mittelböck, R. Jakesz and A. Reiner</i>	
	Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy	45
	<i>P.C. Willsher, J.F.R. Robertson, S.Y. Chan, L. Jackson and R.W. Blamey</i>	
	Haemostatic abnormalities in lung cancer: prognostic implications	50
	<i>G. Buccheri, D. Ferrigno, C. Ginardi and C. Zuliani</i>	
	Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma	56
	<i>M. Colleoni, G. Liessi, G. Mastrapasqua, P. Nelli, G. Vicario, G. Sgarbossa, F. Pancheri and P. Manente</i>	
	Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck	61
	<i>A.S.T. Planting, P.H.M. de Mulder, A. de Graeff and J. Verweij</i>	
	An overview of randomised studies comparing 5-HT ₃ receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting	66
	<i>I.T. Jantunen, V.V. Kataja and T.T. Muhonen</i>	
	Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy	75
	<i>R. Fietkau, M. Riepl, H. Kettner, A. Hinke and R. Sauer</i>	
	Long-term effects of fenretinide on retinal function	80
	<i>A. Decensi, V. Fontana, M. Fioretto, G. Rondanina, R. Torrisi, M.A. Orengo and A. Costa</i>	
Paediatric Oncology		
Paediatric Update	Acute lymphoblastic leukaemia	85
	<i>J. S. Lilleyman</i>	
	Etoposide and thiotepea followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas	91
	<i>E. Bouffet, C. Mottolèse, A. Jouvét, I. Philip, D. Frappaz, C. Carrie and M. Brunat-Mentigny</i>	
Epidemiology and Cancer Prevention		
	Time trend of female breast carcinoma <i>in situ</i> by race and histology in Connecticut, U.S.A.	96
	<i>T. Zheng, T.R. Holford, Y. Chen, B.A. Jones, J. Flannery and P. Boyle</i>	
	Diet and prostate cancer: a case-control study	101
	<i>H.D. Vlahinac, J.M. Marinković, M.D. Ilić and N.I. Koccev</i>	
Experimental Oncology		
	Carcino-embryonic antigen in monitoring the growth of human colon adenocarcinoma tumour cells SK-CO-1 and HT-29 <i>in vitro</i> and in nude mice	108
	<i>G. Solétormos, J.M. Fogh, B. Sehested-Hansen, M. Spang-Thomsen, V. Schiøler, P. Dombrowsky and T. Skovsgaard</i>	

	Detection of the <i>TP53</i> tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer <i>K. Angelopoulou and E.P. Diamandis</i>	115
	Enhancement of antitumour activity of cisplatin by <i>N,N</i> -diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine-HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin <i>K. Kudoh, Y. Kikuchi, H. Hiramatsu, J. Hirata, K. Yamamoto, T. Kita and I. Nagata</i>	122
	Immunohistochemical examination of the expression of <i>O</i> ⁶ -methylguanine-DNA methyltransferase in human melanoma metastases <i>S. Egyházi, G.P. Murgison, J. Hansson and U. Ringborg</i>	129
	Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system <i>P.A. Riley, C.J. Cocksey, C.I. Johnson, E.J. Land, A.M. Latter and C.A. Ramsden</i>	135
	High and low dose rate irradiation have opposing effects on cytokine gene expression in human glioblastoma cell lines <i>H.J. Ross, A.L. Canada, R.J. Antoniono and J.L. Redpath</i>	144
	Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat <i>P. Bergström, A. Jönsson, E. Cavallin-Ståhl, T. Bergenheim and R. Henriksson</i>	153
Short Communication	A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study <i>G. Aravantinos, D.V. Skarlos, P. Kosmidis, A. Athanassiades, D. Bafaloukos, T. Giannakakis, S. Karpathios and G. Fountzilas</i>	160
Book Review	Cancer Care in the Community & Cancer Care in the Hospital, Edited by B. Hancock, Radcliffe Medical Press, Oxford/New York, 1996 <i>W.F. Jungi</i>	164
Letters	Comments on <i>Current and Future Trends in the Multidisciplinary Approach for High-risk Breast Cancer. The Experience of the Milan Cancer Institute</i> , Bonadonna, <i>Eur J Cancer</i> , 32A, No. 2, pp. 209-214 1996 <i>I Barišta</i>	164
	13- <i>cis</i> -retinoic acid and alpha-interferon in advanced squamous cell cancer of the oesophagus <i>T.C. Kok, A. van der Gaast and T.A.W. Splinter</i>	165
	Oral tegafur and folinic acid for the treatment of advanced colorectal cancer <i>M.D. Isla, J.I. Mayordomo, R. Cajal, A. Sáenz, P. Escudero and A. Tres</i>	166
	Sjögren's syndrome and multiple myeloma <i>A. Rodríguez-Cuartero and A. Salas-Galan</i>	167

Vinorelbine in pregnancy <i>C. Cuvier, M. Espie, J.M. Extra and M. Marty</i>	168
Pneumothorax following induction chemotherapy for a germ cell tumour <i>F.M. Laurence, G.B. Zulian and P.Y. Dietrich</i>	169
2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia <i>K. Warzocha, K. Fabianowska-Majewska, J. Błoński, E. Krykowski and T. Robak</i>	170
ECCO 9 Abstract Reproduction Form	I
Referees: January--December 1996	V
<i>Calendar of Forthcoming Meetings</i>	XI
Information for Authors	XV

NUMBER 2

<i>International Cancer News</i>	175
<i>Editorial</i>	
Current status of chemotherapy in advanced seminoma <i>S.D. Fosså and A. Horwich</i>	181
<i>Point of View</i>	
Ethical issues in cancer clinical trials: a European perspective <i>D. Lacombe</i>	184
<i>Review</i>	
Pretargeting strategies for radio-immunoguided tumour localisation and therapy <i>H.S. Stoldt, F. Aftab, M. Chinol, G. Paganelli, F. Luca, A. Testori and J.G. Geraghty</i>	186
<i>Clinical Oncology</i>	
Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial <i>G. Liljegren, L. Holmberg and The Uppsala-Örebro Breast Cancer Study Group</i>	193
The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage I cutaneous melanoma <i>C.R. Rossi, A. Seno, A. Vecchiato, M. Foletto, A. Tregnaghi, A. De Candia, L. Rubaltelli, C. Montesco and M. Lise</i>	200
Temporary tracheobronchial stenting in malignant stenoses <i>Ch. Witt, S. Linges, B. Schmidt, R. Ewert, V. Budach and G. Baumann</i>	204

	Bile duct stents: is there an increased rate of complications in patients receiving chemotherapy? <i>F.J. Lofts, T.R.J. Evans, J.L. Mansi, J.P. Glees and M.J. Knight</i>	209
	Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer <i>A. de Gramont, J. Vignoud, C. Tournigand, C. Louvet, T. André, C. Varette, E. Raymond, S. Moreau, N. Le Bail and M. Krulik</i>	214
	Randomised study of high-dose epirubicin versus high-dose epirubicin--cisplatin chemotherapy for advanced soft tissue sarcoma <i>S. Jelić, V. Kovčin, N. Milanović, N. Babović, M. Kreačić, Z. Ristović, M. Vlajić and I. Filipović-Lješković</i>	220
	Recombinant tumour necrosis factor in the local therapy of malignant pleural effusion <i>G. Rauthe and J. Sistermanns</i>	226
Paediatric Oncology	Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology <i>J.-C. Gentet, M. Brunat-Mentigny, M.C. Demaille, F. Pein, H. Avet-Loiseau, C. Berger, L. De Lumley, H. Pacquement, C. Schmitt, E. Sariban, P. Pilon, J.L. Bernard and C. Kalifa</i>	232
Announcement	Paediatric Update Series	238
	EWS-FLI1 fusion transcripts identified in patients with typical neuroblastoma <i>S.A. Burchill, J. Wheeldon, C. Cullinane and I.J. Lewis</i>	239
Epidemiology and Cancer Prevention	Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients <i>E. Hoff Wanderås, S.D. Fosså and S. Trethli</i>	244
	Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients <i>E. Hoff Wanderås, S.D. Fosså and S. Trethli</i>	253
Experimental Oncology	Co-ordinated changes in expression of cell adhesion molecules in prostate cancer <i>S.J. Murant, J. Handley, M. Stower, N. Reid, O. Cussenot and N.J. Maitland</i>	263
	A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine <i>B.C. Baguley, F. Leteurtre, J.-F. Riou, G.J. Finlay and Y. Pommier</i>	272
	Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines <i>J.S. Macpherson, J. Cummings, I. Meikle, E.P. Müller and J.F. Smyth</i>	280
	Combination of the new minor groove alkylator tallimustine and melphalan <i>G. Tagliabue, C. Filippini, P. Ubezio and M. D'Incalci</i>	284

	Expression of neural <i>BC1</i> RNA: induction in murine tumours	288
	<i>W. Chen, J. Heierhorst, J. Brosius and H. Tiedge</i>	
	Benign and malignant thyroid lesions show instability at microsatellite loci	293
	<i>P. Soares, N.R. dos Santos, R. Seruca, R.A. Lothe and M. Sobrinho-Simões</i>	
Short Communications	Effectiveness of cold cap in the prevention of docetaxel-induced alopecia	297
	<i>M. Lemenager, S. Lecomte, M.E. Bonnetterre, E. Bessa, J. Dauba and J. Bonnetterre</i>	
	Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer	301
	<i>R. Sorio, I. Robieux, E. Galligioni, A. Freschi, A.M. Colussi, D. Crivellari, S. Saracchini and S. Monfardini</i>	
	Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2	304
	<i>P. Lissoni, M. Cazzaniga, S. Barni, M.S. Perego, F. Brivio, L. Fumagalli and G. Tancini</i>	
	Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma	307
	<i>R.I. Young, M. Ranson, J. Chang, B. Lord, N. Testa and J.H. Scarffe</i>	
	Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study	312
	<i>A. Barnadas, C. Mendiola, A. Casado, A. Villar, J. Jimeno, M. Clerigue, R. Rosell, E. Diaz-Rubio, H. Cortés-Funes and M. García de Paredes</i>	
Book Review	Immunodeficient Animals: Models for Cancer Research	316
	<i>Edited by W. Arnold, P. Köpf-Maier and B. Michael</i>	
Letters	Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma	317
	<i>D. Mack, G.W. Hacker, C. Hauser-Kronberger, J. Frick and O. Dietze</i>	
	Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil	318
	<i>M. Benasso, G. Numico and M. Merlano</i>	
	Oral glutamine in the prevention of chemotherapy-induced gastrointestinal toxicity	319
	<i>M. Muscaritola, A. Micozzi, L. Conversano, P. Martino, M.C. Petti, C. Cartoni, A. Cascino and F.R. Fanelli</i>	
	Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure	321
	<i>M. Colleoni, P. Nelli, G. Vicario, G. Sgarbossa, F. Pancheri and P. Manente</i>	
Calendar of Forthcoming Meetings		I
Information for Authors		V

NUMBER 3

International Cancer News		323
Editorial		
	Prostate cancer, populations, politicians and power <i>D. Raghavan</i>	329
Special Paper		
	Follow-up of patients operated on for stage I melanoma: the report of the French Consensus Conference, 1995. English translation of the French document, first published in the <i>Annals de Dermatologie et de Vénéréologie</i> 1995, Vol. 122, pp. 250–258 <i>P. Saiag and E. Grosshans</i>	331
Clinical Oncology Updates	Prostate Cancer—Part I: Epidemiology and Prevention	
	Recent developments in the epidemiology of prostate cancer <i>C. Mettlin</i>	340
	Is screening for prostate cancer the current gold standard?—"No" <i>B.S. Kramer, J.K. Gohagan and P.C. Prorok</i>	348
	Is screening for prostate cancer the current gold standard?—"Yes" <i>P.H. Lange</i>	354
Clinical Oncology		
	The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience <i>T. Wiklund, G. Saeter, H. Strander, T. Alvegård and C. Blomqvist</i>	357
	Tumour biological features of <i>BRCA1</i> -induced breast and ovarian cancer <i>Ö.T. Jóhannsson, I. Idvall, C. Anderson, Å. Borg, R.B. Barkardóttir, V. Egilsson and H. Olsson</i>	362
	Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer <i>R. Haas, H. Schmid, U. Hahn, S. Hohaus, H. Goldschmidt, S. Murea, M. Kaufmann, M. Wannenmacher, D. Wallwiener, G. Bastert and W. Hunstein</i>	372
	Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum <i>A. du Bois, H.J. Lück, K. Buser, H.G. Meerpohl, C. Sessa, U. Klaassen, H. Meden, H. Bochtler and K. Diergarten</i>	379
	Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients <i>J.M. Bréchet, S. Chevreton, J. Nataf, C. Le Gall, J. Frétau, J. Rochemaure and Cl. Chastang</i>	385
	Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study <i>C. Gridelli, F. Perrone, C. Gallo, F. De Marinis, G. Ianniello, S. Cigolari, S. Cariello, F. Di Costanzo, M. D'Aprile, A. Rossi, R. Migliorino, R. Bartolucci, A.R. Bianco, M. Pergola and S. Monfardini</i>	392

	A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy <i>C.E. Nightingale, A. Norman, D. Cunningham, J. Young, A. Webb and J. Filshie</i>	398
	Assay of E-cadherin by ELISA in human breast cancers <i>T.M. Maguire, S.G. Shering, E.W. McDermott, N. O'Higgins, J.J. Fennelly, J. Crown and M.J. Duffy</i>	404
Paediatric Oncology		
Paediatric Update	Wilms' tumour <i>D.M. Green</i>	409
	Commentary on Wilms' tumour <i>J. De Kraker</i>	419
	The effect of the neuroblastoma-seeking agent <i>meta</i> -iodobenzylguanidine (MIBG) on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles <i>J. Cornelissen, A.B.P. Van Kuilenburg, P.A. Voûte and A.H. Van Gennip</i>	421
Epidemiology and Cancer Prevention		
	Effect of age on the survival of breast cancer patients <i>K. Holli and J. Isola</i>	425
	A comparison of the performance and impact of breast cancer screening programmes in East Anglia, U.K. and Bouches du Rhône, France <i>J. McCann, S. Wait, B. Séradour and N. Day</i>	429
	Improved survival of Hodgkin's patients in South-East Netherlands since 1972 <i>D.J. van Spronsen, I.M. Dijkema, L.W. Vrints, G. Hofstra, M.A. Crommelin, F.L.G. Erdkamp, J.W.W. Coebergh and W.P.M. Breed</i>	436
Experimental Oncology		
	D-21266, a new heterocyclic alkylphospholipid with antitumour activity <i>P. Hilgard, T. Klenner, J. Stekar, G. Nössner, B. Kutscher and J. Engel</i>	442
	Role of <i>O</i> ⁶ -methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line <i>S. Egyházi, M.R. Edgren, J. Hansson, D. Kröckel, B. Mannervik and U. Ringborg</i>	447
	Determination of radiosensitivity in established and primary squamous cell carcinoma cultures using the micronucleus assay <i>A.R. Champion, J.A. Hanson, S.E. Venables, A.D. McGregor and C.C. Gaffney</i>	453
	<i>In vitro</i> synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines <i>A. Photiou, P. Shah, L.K. Leong, J. Moss and S. Retsas</i>	463
	Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells <i>C.L. van der Wilt, K. Smid, G.W. Aherne, P. Noordhuis and G.J. Peters</i>	471

	Spontaneous development of plasmacytomas in a selected subline of BALB/cJ mice <i>S. Silva, Y. Wang, M. Babonits, S. Imreh, F. Wiener and G. Klein</i>	479
	Paclitaxel as a radiosensitiser: a proposed schedule of administration based on <i>in vitro</i> data and pharmacokinetic calculations <i>G.D. Zanelli, M. Quaia, I. Robieux, L. Bujor, M. Santarosa, D. Favaro, A. Spada, C. Caffau, C. Gobitti and M.G. Trovo</i>	486
Short Communications	EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors <i>R. de Wit, A. Pawinsky, G. Stoter, A.T. van Oosterom, S.D. Fosså, R. Paridaens, A. Svedberg and P.H.M. de Mulder</i>	493
	An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma <i>A. Pawinski, A.T. van Oosterom, R. de Wit, S. Fosså, J. Croles, A. Svedberg, M.A. Lentz and P.H.M. de Mulder</i>	496
	Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study <i>M.D. Helsing</i>	500
	A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer <i>K. Mori, T. Hirose, S. Machida, K. Yokoyama and K. Tominaga</i>	503
Book Review	Genetic Predisposition to Cancer. Editors: R.A. Eeles, B.A.J. Ponder, D.F. Easton and A. Horwich <i>M. Lehnert</i>	506
Letters	Letter to the Editor: Comments on <i>Health-related Quality of Life of Adults Surviving Malignancies in Childhood</i> , Apajasalo <i>et al.</i> , <i>Eur J Cancer</i> , 32A, No. 8, pp. 1354-1358, 1996 <i>R.D. Barr, W. Furlong and D. Feeny</i>	506
	Breast cancer and HIV infection: two case reports <i>C. Cuvier, M. Esté, J.M. Extra and M. Marty</i>	507
	Intramedullary spinal cord metastasis from carcinoma of the lung: detection by positron emission tomography <i>M.V. Jayasunderi, J.F. Thompson and M.J. Fulham</i>	508
	Primary mediastinal seminoma <i>Á. Oliveira and É. Vieira</i>	509
Calendar of Forthcoming Meetings		I

NUMBER 4

<i>International Cancer News</i>		511
<i>Editorials</i>		
	Thymus therapy for cancer <i>B.R. Cassileth</i>	517
	The usefulness of screening data for studying the biology of breast cancer <i>J.A. van Donger</i>	519
<i>Current Controversies in Cancer</i>		
	Is histological grading of value for the prognosis of soft tissue sarcomas? <i>Pro: S. Daugaard</i> <i>Contra: W.J. Mooi</i> <i>Arbiter: M. Harris</i>	521
<i>Point of View</i>		
	Radiotherapy-induced second cancers: are we doing enough to protect young patients? <i>R. Epstein, I. Hanham and R. Dale</i>	526
<i>Reviews</i>		
	Thymus therapy for cancer? A criteria-based, systematic review <i>E. Ernst</i>	531
	Colorectal cancer---is there an alternative to 5-FU? <i>H. Bleiberg</i>	536
<i>Meeting Highlight</i>		
	Report on 8th World Congress on Pain, 17--22 August 1996 <i>J. Pereira</i>	542
<i>Clinical Oncology Updates</i>	Prostate Cancer---Part II: Advances in Clinical Management	
	Androgens and prostate cancer: biology, pathology and hormonal therapy <i>S.M. Galbraith and G.M. Duchesne</i>	545
	Progress in the management of T3-4 adenocarcinoma of the prostate <i>A.L. Zietman and W.U. Shipley</i>	555
	The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints <i>N.A. Dawson and D.G. McLeod</i>	560
	Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer <i>D. Raghavan, B. Koczwara and M. Javle</i>	566

Clinical Oncology

- Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway 575
T. Risberg, S. Kaasa, E. Wist and H. Melsom
- S-phase fractions of breast cancer predict overall and post-relapse survival 581
Y. Remvikos, V. Mosseri, B. Asselain, A. Fourquet, J.C. Durand, P. Pouillart and H. Magdelénat
- The minimal effective exemestane dose for endocrine activity in advanced breast cancer 587
E. Bajetta, N. Zilembo, C. Noverasco, A. Martinetti, L. Mariani, L. Ferrari, R. Buzzoni, M. Greco, C. Bartoli, I. Spagnoli, G.M. Danesini, S. Artale and J. Paolini
- A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer 592
G. Bolis, G. Scarfone, F. Zanaboni, A. Villa, M. Presti, M. Melpignano, C. Ferraris, S. Tateo, P. Guarnerio, A. Gentile and F. Parazzini
- Rhabdomyolysis and renal function impairment after isolated limb perfusion—comparison between the effects of perfusion with rhTNF α and a 'triple-drug' regimen 596
P. Hohenberger, J. Haier and P.M. Schlag
- Medroxyprogesterone acetate reduces the *in vitro* production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 602
G. Mantovani, A. Macciò, S. Esu, P. Lai, M.C. Santona, E. Massa, D. Dessì, G.B. Melis and G.S. Del Giacco

Paediatric Oncology

- Announcement* Paediatric Update Series 608
- Mitotic percentage index: a new prognostic factor for childhood medulloblastoma 609
R.J. Gilbertson, E. Jaros, R.H. Perry, P.J. Kelly, J. Lunec and A.D.J. Pearson
- Childhood cancer incidence in Zaragoza and Navarre (Spain): 1973–1987 616
M. Pollán, G. López-Abente, E. Ardanaz, P. Moreo, C. Moreno, A. Vergara and N. Aragonés

Epidemiology and
Cancer Prevention

- Mammographic screening for breast cancer. What cancers do we find? 624
T. Nordén, E. Thurjell, M. Hasselgren, A. Lindgren, A. Norgren, R. Bergström and L. Holmberg
- Attributable risks for hepatocellular carcinoma in Northern Italy 629
C. Braga, C. La Vecchia, E. Negri and S. Franceschi

Experimental
Oncology

- Point of View* Homeobox genes: molecular link between congenital anomalies and cancer 635
R. Anbazhagan and V. Raman
- Inhibition of telomerase activity by cisplatin in human testicular cancer cells 638
A.M. Burger, J.A. Double and D.R. Newell

	Hypofractionated radiation induces a decrease in cell proliferation but no histological damage to organotypic multicellular spheroids of human glioblastomas <i>P. Kaaijk, D. Troost, P. Sminia, M.C.C.M. Hulshof, A.H.W. van der Kracht, S. Leenstra and D.A. Bosch</i>	645
	Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42 <i>E. Moran, I. Cleary, A.M. Larkin, R. Nic Amhlaoibh, A. Masterson, R. J. Scheper, M.A. Izquierdo, M. Center, F. O'Sullivan and M. Clynes</i>	652
	Endothelin expression and responsiveness in human ovarian carcinoma cell lines <i>S. Moraitis, S.P. Langdon and W.R. Miller</i>	661
	Modulation of <i>cis</i> -diamminedichloroplatinum (II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells <i>G. Marverti, F.A. Andrews, G. Piccinini, S. Ghiaroni, D. Barbieri and M.S. Moruzzi</i>	669
	Hydrogen peroxide is involved in lymphocyte activation mechanisms to induce angiogenesis <i>M. Monte, L.E. Davel and E. Sacerdote de Lustig</i>	676
Short Communications	<i>BRCA1</i> mutations found in archived early onset breast tumours <i>A.M. Garvin, U. Eppenberger, H. Müller, S. Eppenberger-Castori and R. J. Scott</i>	683
	Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens <i>E. Bajetta, M. Di Bartolomeo, L. Somma, M. del Vecchio, S. Artale, F. Zunino, P. Bignami, E. Magnani and R. Buzzoni</i>	687
	Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas <i>M. Volm, R. Koomägi, J. Mattern and G. Stämmler</i>	691
Book Review	Prevention and early detection of colorectal cancer. Editors: G.P. Young, P. Rozen and B. Levin <i>W. Inauen</i>	694
Letters	Role of radical prostatectomy in micrometastases dissemination <i>I. Sardi, C. Fatini, R. Ponchiatti and M. Piazzini</i>	694
	Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma <i>E. Raymond, A. de Gramont, C. Louvet, C. Tournigand, B. Demuyneck, K. Beerblock, E. Carola and M. Krulik</i>	696
	Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold <i>W. Yeo, S.F. Leung and P. J. Johnson</i>	698
	Cathepsin D content in malignant tumours of corpus uteri <i>M. Osmak, D. Babić, M. Abramić, I. Vrhovec, D. Miličić and J. Škrk</i>	699
	Correction and Apology	701

Calendar of
Forthcoming
Meetings

I

Information for Authors

V

NUMBER 5

Special Issue: Telomeres and Telomerase in Cancer

Guest editors: Silvia Bacchetti and David Wynford-Thomas

The biology of replicative senescence <i>J. Campisi</i>	703
Multiple pathways to cellular senescence: role of telomerase repressors <i>M. Oshimura and J.C. Barrett</i>	710
Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology <i>D. Wynford-Thomas</i>	716
The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation <i>E.K. Parkinson, R.F. Newbold and W.N. Keith</i>	727
The DNA structures at the ends of eukaryotic chromosomes <i>R.J. Wellinger and D. Sen</i>	735
The implications of telomerase biochemistry for human disease <i>G.B. Morin</i>	750
Multiple pathways for the regulation of telomerase activity <i>S.E. Holt, W.E. Wright and J.W. Shay</i>	761
Telomere dynamics and telomerase activity in <i>in vitro</i> immortalised human cells <i>T.M. Bryan and R.R. Reddel</i>	767
Telomeres and telomerase in normal and malignant haematopoietic cells <i>K.-F. Norrback and G. Roos</i>	774
Clinical implications of telomerase in cancer <i>N.W. Kim</i>	781
A survey of telomerase activity in human cancer <i>J.W. Shay and S. Bacchetti</i>	787
Telomere structure and telomerase expression during mouse development and tumorigenesis <i>D. Kipling</i>	792
Information for Authors	I

NUMBER 6

<i>International Cancer News</i>		801
<i>Editorials</i>		
	Who truly represents the needs of the consumer diagnosed with breast cancer? Who are these patients' advocates? How are they informed? What, if any, are their secret agendas? <i>M. Baum</i>	807
	POMB/ACE chemotherapy for mediastinal germ-cell tumours <i>J.P. Droz</i>	809
	Reliability of cancer registration data <i>C.A. Stiller</i>	812
<i>Current Controversies in Cancer</i>		
	Should patients with advanced colorectal cancer be treated with chemotherapy? <i>Pro: G.H. Blijham</i> <i>Contra: R. Labianca</i> <i>Arbiter: H. Bleiberg</i>	815
<i>Point of View</i>		
	The voice of the breast cancer patient---a lonely cry in the wilderness <i>H. Thornton</i>	825
<i>Special Paper</i>		
	Radiotherapy after chemotherapy for metastatic seminoma---a diminishing role <i>G.M. Duchesne, S.P. Stenning, N. Aass, G.M. Mead, S.D. Fosså, R.T.D. Oliver, A. Horwich, G. Read, I.T. Roberts, G. Rustin, M.H. Cullen, S.B. Kaye, S.J. Harland and P.A. Cook on behalf of the MRC Testicular Tumour Working Party</i>	829
<i>Meeting Highlight</i>		
	Highlights of the Third International Conference in Geriatric Oncology held in Tampa, Florida, 13--15 November 1996 <i>L. Balducci</i>	836
<i>Clinical Oncology</i>		
	POMB/ACE chemotherapy for mediastinal germ cell tumours <i>M. Bower, C. Brock, L. Holden, A. Nelstrop, A.R. Makey, G.J.S. Rustin and E.S. Newlands</i>	838
	Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours <i>J.T. Hartmann, M. Candelaria, M.A. Kuczyk, H.-J. Schmoll and C. Bokemeyer</i>	843
	Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone <i>A. Horwich, L. Specht and S. Ashley</i>	848

	The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19 <i>A. Schoenfeld, K.H. Kruger, J. Gomm, H.D. Sinnott, J.-C. Gazet, N. Sacks, H.G. Bender, Y. Luqmani and R.C. Coombes</i>	854
	Clinical and pathological response to primary chemotherapy in operable breast cancer <i>P. Chollet, S. Charrier, E. Brain, H. Curé, I. van Praagh, V. Feillel, M. de Latour, J. Dauplat, J.-L. Misset and J.-P. Ferrière</i>	862
	Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients <i>H. Pappot, G. Høyer-Hansen, E. Rønne, H.H. Hansen, N. Brønner, K. Danø and J. Grøndahl-Hansen</i>	867
	Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients <i>M. Santarosa, D. Favaro, M. Quaia and E. Galligioni</i>	873
	Disclosing the cancer diagnosis: the patients' experiences <i>J.H. Loge, S. Kaasa and K. Hytten</i>	878
	Communicating with and treating cancer patients: how does the use of non-proven therapies and patients' feeling of mental distress influence the interaction between the patient and the hospital staff <i>T. Risberg, R.M. Bremnes, E. Wist, S. Kaasa and B.K. Jacobsen</i>	883
Paediatric Oncology	Accuracy and completeness of the registration of childhood leukaemia in The Netherlands, 1989–1992 <i>L.J. Schouten, A. Van der Does-van den Berg, R. Otter and J.W.W. Coebergh</i>	891
Paediatric Update	Malignant germ cell tumours in childhood <i>By C.R. Pinkerton with a Commentary by J. Prichard</i>	895
Epidemiology and Cancer Prevention	Trends of <i>in situ</i> carcinoma of the breast in Vaud, Switzerland <i>F. Levi, V.-C. Tè, L. Randimbison and C. La Vecchia</i>	903
	Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality <i>R.R. Nordal and S.Ø. Thoresen</i>	907
Experimental Oncology	Differential immunogenicity of Epstein–Barr virus (EBV) encoded growth transformation-associated antigens in a murine model system <i>P. Trivedi, G. Winberg and G. Klein</i>	912
	Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases <i>O.H. Sanchez-Sweatman, J. Lee, F.W. Orr and G. Singh</i>	918
	High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival <i>A. Dietrich, E. Tanczos, W. Vanscheidt, E. Schöpf and J.C. Simon</i>	926

	Mucins secreted by cell lines derived from colorectal mucinous carcinoma and adenocarcinoma <i>M. Cho, R. Dahya, S.R. Choi, B. Siddiki, M.M. Yeh, M.H. Sleisenger and Y.S. Kim</i>	931
	Response to radiotherapy of human uterine cervix carcinomas is not correlated with rearrangement of the Ha-ras-1 and or c-myc genes <i>A.G. Polischouk, O.I. Scotnikova, N.S. Sergeeva, G.M. Zharinov, R. Lewensohn and B. Zhivotovsky</i>	942
	Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data <i>S. Chéradame, M.-C. Etienne, M. Chazal, T. Guillot, J.-L. Fischel, P. Formento and G. Milano</i>	950
	The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer <i>H. Kawamura, K. Ikeda, I. Takiyama and M. Terashima</i>	960
Short Communications	Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion <i>S. Chiara, M.T. Nobile, C. Barzacchi, O. Sanguineti, M. Vincenti, C. Di Somma, P. Meszaros and R. Rosso</i>	967
	Germ cell cancers in adult males are associated with a history of infantile pyloric stenosis <i>A.B. Hassan and G.M. Mead</i>	970
	Serum M3/M21 in cervical cancer patients <i>G. Sliutz, C. Tempfer, E. Hanzal, A. Reinthaller, H. Koelbl, R. Zeillinger and Ch. Kainz</i>	973
Letters	Contralateral groin node metastasis from lower limb melanoma <i>J.F. Thompson, R.P.M. Saw, M.H. Colman, R.B. Howman-Giles and R.F. Uren</i>	976
	Has radiation therapy any role in signet-ring cell breast adenocarcinoma? <i>V. Ruiz, I. Henríquez, A. Reig, C. Conill and E. Verger</i>	977
	Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy <i>S. Stremetzne, U. Jaehde, R. Kasper, J. Beyer, W. Siegert and W. Schunack</i>	978
Calendar of Forthcoming Meetings		I
	Information for Authors	IV
 NUMBER 7 		
International Cancer News		981
	Evidence based medicine, a new challenge <i>A. Costa and S.M. Hubbard</i>	987

	Aromatase inhibitors for breast cancer—further progress <i>R.D. Rubens</i>	989
	Cancer burden in Europe for 1990: can we predict the figures for the year 2000? <i>J.W.W. Coebergh</i>	991
Special Paper	An evaluation of the NCI Physician Data Query (PDQ) dissemination in Europe <i>C. Arrigo</i>	997
Reviews	Regulation of the eukaryotic cell cycle <i>P. Nurse</i>	1002
	The role of the bystander effect in suicide gene therapy <i>I.M. Pope, G.J. Poston and A.R. Kinsella</i>	1005
Clinical Oncology	Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of amoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90) <i>B. Thürlimann, M. Castiglione, S.F. Hsu-Schmitz, F. Cavalli, H. Bonnefoi, M.F. Fey, R. Morant, T. Löhner and A. Goldhirsch for the Swiss Group for Clinical Cancer Research (SAKK)</i>	1017
	Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy <i>A. Coates, F. Porzsolt and D. Osoba</i>	1025
	Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures <i>F. Blot, M. Guiguet, G. Nitenberg, B. Leclercq, B. Gachot and B. Escudier</i>	1031
	Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer <i>O. Klepp, O. Dahl, P. Flodgren, U. Stierner, A.M. Olsson, J. Oldbring, S. Nilsson, L. Dæhlin, M. Trønbøl, R. Småland, H. Starkhammar, L. Abramsson, E. Wist, N. Raabe, T. Edekling and E. Cavallin-Ståhl</i>	1038
	The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group <i>J. Verweij, O.S. Nielson, P. Therasse and A.T. van Oosterom</i>	1045
	Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2 <i>M. Engelhardt, K. Wirth, R. Mertelsmann, A. Lindemann and U. Brennscheidt</i>	1050
	The role of radiotherapy in the local management of dermatofibrosarcoma protuberans <i>R.L.M. Haas, R.B. Keus, B.M. Loftus, E.J. Th. Rutgers, F. van Coevorden and H. Bartelink on behalf of the Soft Tissue Tumours Working Group</i>	1055

Paediatric Oncology

- Long-term results from the first UKCCSG Ewing's tumour study (ET-1) 1061
A.W. Craft, S.J. Cotterill, J.A. Bullimore and D. Pearson on behalf of the United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party
- The use of SCID mice for the growth of retinoblastoma cell lines and for the establishment of xenografts from primary tumours 1070
J.K. Cowell, P. Ramani, Y. Song, M. Evans and G. Morgan

Epidemiology and
Cancer Prevention

- Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990 1075
R.J. Black, F. Bray, J. Ferlay and D.M. Parkin

Experimental
Oncology

- Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice 1108
C.L. Van Den Berg, G.N. Cox, C.A. Stroh, S.G. Hilsenbeck, C.-N. Weng, M.J. McDermott, D. Pratt, C.K. Osborne, E.B. Coronado-Heinsohn and D. Yee
- Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat 1114
F. Burke, N. East, C. Upton, K. Patel and F.R. Balkwill
- Antiproliferative effects of paclitaxel (Taxol®) on human renal clear cell carcinomas *in vitro* 1122
P. Reinecke, J. Corvin, H.E. Gabbert and C.D. Gerharz
- The effect of Onapristone, a progesterone antagonist, on the growth of human gastrointestinal cancer xenografts 1130
E. Jacobs, S.A. Watson, I.O. Ellis, J.D. Hardcastle and J.F.R. Robertson
- TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns 1136
K. Hanada, M. Itoh, K. Fujii, A. Tsuchida, M. Hirata, T. Iwao, N. Eguchi, T. Sasaki, K. Matsubara and G. Kajiyama
- Inhibition of growth of androgen-independent DU-145 prostate cancer *in vivo* by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II 1141
A. Jungwirth, J. Pinski, G. Galvan, G. Halmos, K. Szepeshazi, R.Z. Cai, K. Groot, M. Vadillo Buenfil and A.V. Schall

Short
Communications

- A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer 1149
P. Savage, D. Costelna, J. Moore and M.E. Gore
- Chemo-radiotherapy for locally advanced head and neck cancer—long-term results of a phase II trial 1152
S. Dinges, V. Budach, M. Stuschke, W. Budach, D. Boehmer, M. Schrader, K. Jahnke and H. Sack

Letters

- Letters to the Editor: Comments on *Swiss Plan to Fight Against Breast Cancer*, International Cancer News, *Eur J Cancer*, 32A, No. 11, pp. 1830–1831, 1996 1156

(i) J. H. Weisburger

(ii) Response from: I. Rajower, A.J. Sasco and P. Kleihues

- Primary treatment in stage II non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? 1157

T.F. Sandeman

Calendar of
Forthcoming
Meetings

I

Information for Authors

NUMBER 8

Editorials

- Understanding patient preferences for involvement in care 1169
P.A. Ganz

- Vascular access devices in cancer patients: towards the next step 1171
C.O. Freytes

Special Paper

- EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer 1173
A. Awada, A. Van Vreckem, R. Paridaens, P.F. Bruning, J. Klijn, E. Tomiak, J. Vinholes, J.A. Roy, Z. Kusenda, G. Hocht Boes, M. Van Glabbeke and M.J. Piccart on behalf of EORTC-IDBBC

Review

- Oestrogen receptor mutants and variants in breast cancer 1177
M. Dowsett, A. Daffada, C.M.W. Chan and S.R.D. Johnston

Clinical Oncology

- Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it 1184
D. Rothenbacher, M.P. Lutz and F. Porzsolt

- Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device 1190
R. Biffi, F. Corrado, F. de Braud, F. de Lucia, D. Scarpa, A. Testori, F. Orsi, M. Bellomi, S. Mauri, M. Aapro and B. Andreoni

- CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma 1195
D.A. Cameron, J.M. White, S.J. Proctor, R.J. Prescott, R.C.F. Leonard B. Angus, M.K. Cook, P.J.D.K. Dawes, A.A. Dawson, R.G.B. Evans, M.J. Galloway, A.L. Harris, A. Heppleston, C.H.W. Horne, A.S. Krajewski, A.L. Lennard, A.M. Lessells, H.H. Lucraft, J.B. MacGillivray, M.J. Mackie, A.C. Parker, J.T. Roberts, P.R.A. Taylor, W.D. Thompson on behalf of the Scotland and Newcastle Lymphoma Group

Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses <i>C.N. Baxevanis, N.B. Tsavaris, S.I. Papadimitriou, I.K. Zarkadis, N.G. Papadopoulos, E.A. Bastounis and M. Papamichail</i>	1202
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987) <i>D. Nitti, J. Wils, T. Sahmoud, D. Curran, M.L. Couvreur, M. Lise, H. Rauschecker, J. Guimaraes dos Santos, W. Stremmel and F. Roelofsen</i>	1209
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer <i>H. Bleiberg, T. Conroy, B. Pailot, A.J. Lacave, G. Blijham, J.H. Jacob, L. Bedenne, M. Namer, P. De Besi, F. Gay, L. Collette and T. Sahmoud</i>	1216
Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: do histological assessment and p53 over-expression predict chemo-responsiveness? <i>K.-Y. Lam, S. Law, L.T. Ma, S.-K. Ong and J. Wong</i>	1221
Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer <i>X. Filella, J. Alcover, R. Molina, A. Rodríguez, P. Carretero and A. M. Ballesta</i>	1226
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen <i>D. Chao, M. von Schlippe and S.J. Harland</i>	1230
Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET <i>J.M. Nuutinen, S. Leskinen, I. Elomaa, H. Minn, M. Varpula, O. Solin, K.-O. Söderström, H. Joensuu and E. Salminen</i>	1234

Paediatric Oncology

Announcement

Paediatric Update Series	1242
Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma <i>D. von Schweinitz, D.J. Byrd*, H. Hecker, P. Weinl, U. Bode, D. Bürger, R. Ertmann, D. Harms and H. Mildenberger</i> <i>For the Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology</i>	1243
Anxiety and depression in adolescent cancer: findings in patients and parents at the time of diagnosis <i>R. Allen, S.P. Newman and R.L. Souhami</i>	1250

Epidemiology and
Cancer Prevention

Vegetable and fruit intake and the risk of lung cancer in women in Barcelona, Spain <i>A. Agudo, M.G. Esteve, C. Pallarès, I. Martínez-Ballarín, X. Fabregat, N. Malats, I. Machengs, A. Badia and C.A. González</i>	1256
Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy <i>G. Ronco, N. Segnan, L. Giordano, S. Pilutti, C. Senore, A. Ponti and R. Volante</i>	1262

Experimental
Oncology

p53 expression is of independent predictive value in lymph node-negative breast carcinoma <i>M. Fresno, R. Molina, M. J. Pérez del Río, S. Alvarez, J. M. Díaz-Iglesias, I. García and A. Herrero</i>	1268
Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with multifocality, histopathological types and prognosis <i>C. S. Papadimitriou, J. S. Costopoulos, B. P. Christoforidou, A. J. Kotsianti, G. S. Karkavelas, P. M. Hytioglou, D. J. Koufogiannis and H. E. Nenopoulou</i>	1275
TP53 mutation in ovarian carcinoma <i>M. Murphy, D. T. McManus, P. G. Toner and S. E. H. Russell</i>	1281
Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells <i>G. Corona, G. Toffoli, M. Fabris, A. Viel, A. Zarrelli, C. Donada and M. Boiocchi</i>	1284
Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids <i>K. M. Nicholson, M. C. Bibby and R. M. Phillips</i>	1291
Enhanced radioreponse of paclitaxel-sensitive and -resistant tumours <i>in vivo</i> <i>C. G. Milross, K. A. Mason, N. R. Hunter, N. H. A. Terry, N. Patel, S. Harada, T. Jibu, J. Seong and L. Milas</i>	1299
Telomerase activity and its clinicopathological significance in gastric cancer <i>M. -J. Ahn, Y. H. Noh, Y. S. Lee, J. H. Lee, T. J. Chung, I. S. Kim, I. Y. Choi, S. H. Kim, J. S. Lee and K. H. Lee</i>	1309
The status of p53 in the metastatic progression of colorectal cancer <i>I. Heide, C. Thieäe, T. Sonntag, E. de Kant, A. Neubauer, S. Jonas, F. J. Peter, P. Neuhaus, R. Herrmann, D. Huhn and C. F. Rochlitz</i>	1314

Short
Communications

Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma <i>A. Avilés, J. C. Díaz-Maqueo, A. Talavera, E. L. García, R. Guzmán and M. J. Nambo</i>	1323
Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma <i>P. Comella, A. Daponte, R. Casaretti, F. Ionna, F. Fiore, F. Presutti, G. Frasci, F. Caponigro, A. Gravina, A. P. Parziale, N. Mozzillo and G. Comella</i>	1326
Ambulatory narrow excision for thin melanoma (≤ 2 mm): results of a prospective study <i>A. Bono, C. Baroli, C. Clemente, I. Del Prato, P. Boracchi, N. Rossi and N. Cascinelli</i>	1330

Letters

Comments on adaptation of the cell scan technique for the SCM test in breast cancer (i) <i>S. Birindelli, M. I. Colnaghi and S. Pilotti</i>	1333
(ii) Response from Rahmani and associates <i>H. Rahmani, M. Deutsch, I. Rom, S. Gerbat, R. Tirosh, A. Weinreb, S. Chaichik and S. Lalchuk</i>	1334

Non-steroidal anti-inflammatory drugs in the treatment of colorectal cancer <i>G. Morgan</i>	1335
---	------

<i>Correction</i>	1337
-------------------	------

<i>Calendar of Forthcoming Meetings</i>	I
---	---

Information for Authors	IV
-------------------------	----

NUMBER 9

<i>International Cancer News</i>	1339
--------------------------------------	------

Editorials

Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity <i>B.E. Hillner and J.M. Kirkwood</i>	1345
---	------

Prognostic factors for advanced seminoma---a solid basis for clinical trials <i>H.-J. Schmoll</i>	1347
--	------

Current Controversies in Cancer

Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?	1351
--	------

Pro: P. Reichardt

Contra: J. Verweij

Arbiter: D. Crowther

Special Paper

Phase II trials in the EORTC	1361
------------------------------	------

The Protocol Review Committee, the Data Center, the Research and Treatment Division, and the New Drug Development Office

Review

5-HT ₃ receptor antagonists: differences and similarities	1364
--	------

F. Roila, E. Bialiari, M. Tonato and A. Del Favero

Meeting Highlight

Cochrane Cancer Clan Gathers in Brussels	1371
--	------

C. Williams

Clinical Oncology

A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma	1373
--	------

A. Messori, P. Becagli, S. Trippoli and E. Tendi

Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy <i>S.D. Fossa, R.T.D. Oliver, S.P. Stenning, A. Horwich, P. Wilkinson, G. Read, G.M. Mead, J.T. Roberts, G. Rustin, M.H. Cullen, S.B. Kaye, S.J. Harland and P. Cook</i>	1380
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma <i>P.N. Mainwaring, H. Atkinson, J. Chang, J. Moore, B.W. Hancock, P.J. Guillou, R. Oskam and M.E. Gore</i>	1388
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy <i>T. Berger, R. Malayeri, A. Doppelbauer, G. Krajnik, H. Huber, E. Auff and R. Pirker</i>	1393
Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer <i>P. Soulié, A. Bensmaïne, C. Garrino, P. Chollet, E. Brain, M. Fereres, C. Jasmin, M. Musset, J.L. Misset and E. Cvitkovic</i>	1400
Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer <i>R. Nishimura, K. Nagao, M. Matsuda, K. Baba, Y. Matsuoka, H. Yamashita, M. Fukuda, A. Higuchi and K. Ikeda</i>	1407
Carcinoma of the stomach following the Chernobyl nuclear accident <i>I.B. Shchepotin, V.L. Valetsky, V.A. Chorny, M. Shabahang, R.J. Nauta, R.R. Buras and S.R.T. Evans</i>	1413
Paclitaxel changes sympathetic control of blood pressure <i>E. Ekholm, V. Rantanen, K. Antila and E. Salminen</i>	1419
Pharmacokinetics of amifostine and its metabolites in patients <i>A.E.C. Korst, C.M. Eeltink, J.B. Vermorken and W.J.F. van der Vijgh</i>	1425

Paediatric Oncology

<i>Paediatric Update</i>	Neuroblastoma	1430
	<i>By R.P. Castleberry with a Commentary by F. Berthold</i>	
	The U.S. pediatric cancer clinical trials programmes: international implications and the way forward <i>W.A. Bleyer</i>	1439
	The United Kingdom Children's Cancer Study Group—the first 20 years of growth and development <i>M.G. Mott, J.R. Mann and C.A. Stiller on behalf of the UKCCSG</i>	1448

Epidemiology and Cancer Prevention

Interval cancers and cancers in non-attenders in the Östergötland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence <i>B. Vitak, O. Stål, J.C. Manson, B.A. Thomas, L.G. Arnesson, L. Ekelund, K. Måre, B. Nordenskjöld, A.-C. Källström and H. Bång</i>	1453
Duration of colorectal cancer symptoms and survival: the effect of confounding clinical and pathological variables <i>H.E. Mulcahy and D.P. O'Donoghue</i>	1461

Experimental
Oncology

Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer <i>V.A. Ferro and W.H. Stimson</i>	1468
An intronic deletion in <i>TP53</i> gene causes exon 6 skipping in breast cancer <i>G. Voglino, S. Castello, L. Silengo, G. Stefanuto, O. Friard, G. Ferrara and L. Fessia</i>	1479
Differential binding of nuclear proteins to the <i>TP53</i> gene promoter in male breast tumour <i>B.K. Nayak and B.R. Das</i>	1484
Quantification of additional short arms of chromosome 12 in germ cell tumours using the polymerase chain reaction <i>N.P. Malek, J. Casper, L.H.J. Looijenga, T. Strohmeyer, H.-J. Schmoll, A. Nordheim and R. Janknecht</i>	1488
Game-theory models of interactions between tumour cells <i>I.P.M. Tomlinson</i>	1495
Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas <i>M. Mandai, I. Konishi, H. Kuroda, M. Fukumoto, T. Komatsu, S. Yamamoto, K. Nanbu, Ch.V. Rao and T. Mori</i>	1501
Cytosolic phospholipase A ₂ , cyclo-oxygenases and arachidonate in human stomach tumours <i>A.S. Soydan, J.D. Gaffen, P.K. Weech, N.M. Tremblay, S. Kargman, G. O'Neill, A. Bennett and I.A. Tavares</i>	1508

Short
Communications

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC gynaecological cancer cooperative group study <i>M.E.L. van der Burg, G. Bolis, P.J.M. Bakker, D. Curran, T. Sahmoud and J.B. Vermorken</i>	1513
<i>MDR1</i> RNA transcripts do not indicate long-term prognosis in colorectal carcinomas <i>S. Zöchbauer, J. Wallner, K. Haider, D. Depisch, H. Huber and R. Pirker</i>	1516

Letters

Remarkable age-dependent sex differences in the incidence of adenocarcinoma of the gastric cardia and oesophagus in The Netherlands <i>L.J. Schouten and L.A.L.M. Kiemeny</i>	1519
Artifactual hypoglycaemia during treatment with filgrastim (rHu-met-G-CSF) <i>J.J. Illarramendi, A. Iruin and I. Muxelena</i>	1520

Calendar of
Forthcoming
Meetings

NUMBER 10

<i>International Cancer News</i>		1521
<i>Editorials</i>		
Etoposide for soft tissue sarcomas: fact or fiction <i>J. Verweij</i>		1527
Obesity and ovarian cancer <i>C. Frost and M.P. Coleman</i>		1529
<i>Point of View</i>		
Impaired ovulation and breast cancer risk <i>B.A. Stoll</i>		1532
<i>Special Paper</i>		
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe <i>H. Bleiberg, B. Gerard, J. Wils, G. Blijham, E. Diaz-Rubio, R. Herrmann, D. Kerr, R. Labianca, Ph. Rougier, H.J. Wilke and N. Wilking</i>		1536
<i>Review</i>		
Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion <i>J. van der Zee, B.B.R. Kroon, O.E. Nieweg, S.A. van de Merwe and H.H. Kampinga</i>		1546
<i>Clinical Oncology</i>		
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian sarcoma group phase II study <i>G. Sæter, T.A. Aivégård, O.R. Monge, H. Strander, I. Turesson, R. Klepp, M. Söderberg, E. Wist, N. Raabe, M. Erlanson, Ø.P. Solheim and E. Hannisdal</i>		1551
Ten-year results of treatment of ductal carcinoma <i>in situ</i> (DCIS) of the breast with conservative surgery and radiotherapy <i>M. Amichetti, O. Caffo, A. Richetti, G. Zini, A. Rigon, M. Antonello, M. Arcicasa, F. Coghetto, R. Valdagni, S. Maluta and A. Di Marco</i>		1559
A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and l-folinic acid in patients with metastatic colorectal cancer <i>C. Garufi, F. Lévi, A.M. Aschelter, R. Pace, S. Giunta, C. Nisticò, D.A.P. Gallà, G.F. Silecchia, F. Franchi, C. Narduzzi and E. Terzoli</i>		1566
The clinicopathological significance of <i>K-RAS</i> point mutation and gene amplification in endometrial cancer <i>M. Esteller, A. García, J.M. Martínez-Palones, J. Xercavins and J. Reventós</i>		1572
The bone isoenzyme of alkaline phosphatase in hypercalcaemic cancer patients <i>J.J. Body, J.C. Dumon, D. Blocklet and C. Darte</i>		1578
A dose-controlled study of ¹⁵³ Sm-Ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases <i>I. Resche, J.-F. Chatal, A. Pecking, P. Ell, G. Duchesne, R. Rubens, I. Fogelman, S. Houston, A. Fauser, M. Fischer and D. Wilkins</i>		1583

	Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study <i>A.A. Brandes, E. Scelzi, G. Salmistraro, M. Ermani, C. Carollo, F. Berti, P. Zampieri, C. Baiocchi and M.V. Fiorentino</i>	1592
	Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital <i>N. Aass, S.D. Fosså, A.A. Dahl and T. Moe</i>	1597
	A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy <i>V. Kirchner, M. Aapro, J.-P. Terrey and P. Alberto</i>	1605
Paediatric Oncology		
Paediatric Update		
	Osteosarcoma <i>By J.S. Whelan with a Commentary by V.H.C. Bramwell</i>	1611
	Phase I study of interleukin-6 in children with solid tumours in relapse <i>E. Bouffet, T. Philip, C. Negrier, M. French, D. Frappaz, O. Gentilhomme, A. Gianella-Borradori, M. Brunat-Mentigny and J.Y. Blay</i>	1620
	Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients <i>M. Iastowska, S. Cotterill, A. D. J. Pearson, P. Roberts, A. McGuckin, I. Lewis and N. Bown</i> <i>On behalf of the U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group</i>	1627
Epidemiology and Cancer Prevention		
	Ovarian cancer risk and history of selected medical conditions linked with female hormones <i>F. Parazzini, S. Moroni, C. La Vecchia, E. Negri, D. dal Pino and G. Bolis</i>	1634
	Hodgkin's disease in patients older than 70 years of age: a registry-based analysis <i>P.D. Forsyth, E.M. Bessell, A.J. Moloney, I.H. Leach, J.M. Davies and J. Fletcher</i>	1638
	Changes in lung cancer histological types in Varese cancer registry, Italy 1976–1992 <i>A. Russo, P. Crosignani, S. Franceschi and F. Berrino</i>	1643
Experimental Oncology		
	Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1 <i>C. Van Pachterbeke, M. Tuynder, A. Brandenburger, G. Leclercq, M. Borras and J. Rommelaere</i>	1648
	Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content <i>J.D. Graham, R.L. Balleine, J.S. Milliken, A.M. Bilous and C.L. Clarke</i>	1654
	Tumour-derived, endocrine, exogenous and therapeutic factors differentially modulate cytokine secretion in whole blood cell culture <i>J.R. Fischer, M. Schindel, H. Lahm and P. Drings</i>	1661
	Cellular responses to methyl-N-[4-(9-acridinylamino)-2-methoxyphenyl]carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells <i>N. Moreland, G.J. Finlay, M. Dragunow, K.M. Holdaway and B.C. Baguley</i>	1668

	Genome wide search for genetic damage in p53 transgenic mouse lung tumours reveals consistent loss of chromosome 4 <i>M.-C. Wu, M. Sundareshan, V. Sundareshan and P. Rabbits</i>	1677
	Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9 <i>A. Vacca, S. Moretti, D. Ribatti, A. Pellegrino, N. Pimpinelli, B. Bianchi, E. Bonifazi, R. Ria, G. Serio and F. Dammacco</i>	1685
	Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained <i>C.W. Taylor, L.M. Wang, A.F. List, D. Fernandes, G.D. Paine-Murrieta, C.S. Johnson and R.L. Capizzi</i>	1693
Short Communications	A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer <i>S. Cascinu, R. Ficarelli, M.A.A. Safi, F. Graziano, G. Catalano and R. Cellerino</i>	1699
	Interleukin-12 in early or advanced cancer patients <i>P. Lissoni, F. Rovelli, S. Pittalis, M. Casati, M.S. Perego, M.G. Grassi, F. Brivio and L. Fumagalli</i>	1703
Book Review	Cancer genes: functional aspects. Editors: Enrico Mihich and David Housman <i>R. J. Scott</i>	1706
Letters	Comments on <i>Inadequacy of iridium implant as sole radiation treatment for operable breast cancer</i> , Fentiman <i>et al.</i> , <i>Eur J Cancer</i> 32A , No. 4, pp. 608-611 (i) <i>R.G. Dale, B. Jones and P. Price</i>	1707
	(ii) Response from I.S. Fentiman and D. Tong <i>I.S. Fentiman and D. Tong</i>	1708
	An unusual case of renin-producing tumour of the fallopian tube <i>A. Zubernigg, E. Müller-Holzner, J.-M. Gasc and C. Gatringer</i>	1709
Calendar of Forthcoming Meetings		I
	Information for Authors	XI
	NUMBER 11	
International Cancer News		1711
Editorial	Small cell lung cancer and prophylactic cranial irradiation (PCI): perhaps the question is not who needs PCI but who wants PCI? <i>T. Le Chevalier and R. Arriagada</i>	1717

Current Controversies in Cancer	Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (≥ 70 years of age) <i>Pro: L. Balducci and M. Extermann</i> <i>Contra: I. Fentiman</i> <i>Arbiter: S. Monfardini and F. Perrone</i>	1720
Point of View	On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy <i>Ø.S. Bruland and A. Pihl</i>	1725
Special Paper	A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC <i>A. J. Croockewit, M. H. Bronchud, M. S. Apro, M. J. Bargetzi, J. Crown, A. Gratwohl, W. Lange, H. Ludwig, G. Martinelli, R. Mertelsmann, V. Nuessler, R. Willemze, T. J. M. De Witte, R. Zittoun, H. Zwierzina</i>	1732
Review	Modern brachytherapy: current state and future prospects <i>P. Nickers, I. Kunkler and P. Scalliet</i>	1747
Clinical Oncology	Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial <i>A. Gregor, A. Cull, R. J. Stephens, J. A. Kirkpatrick, J. R. Yarnold, D. J. Girling, F. R. Macbeth, R. Stout and D. Machin on behalf of the United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC)</i>	1752
	Role of recombinant interferon gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC lung cancer cooperative group <i>N. van Zandwijk, H. J. M. Groen, P. E. Postmus, J. Th. W. Burghouts, G. P. M. ten Velde, A. Ardizzoni, I. E. Smith, P. Bass, T. Sahmoud, A. Kirkpatrick, O. Dalesio and G. Giaccone for the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group</i>	1759
	Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study <i>B. Thürlimann, R. Paridaens, D. Serin, J. Bonnetterre, H. Roché, R. Murray, E. di Salle, S. Lanzaone, M. G. Zurlo and G. Piscitelli on behalf of the Exemestane Study Group</i>	1767
	The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer <i>J. F. R. Robertson, P. C. Willsher, K. L. Cheung and R. W. Blamey</i>	1774
	Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers <i>G. P. Stathopoulos, S. Rigatos, P. Papakostas and G. Fountzilas</i>	1780
	Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients, a phase II study <i>E. Bobbio-Pallavicini, C. Porta, M. Moroni, G. Bertulezzi, L. Civelli, P. Pugliese and G. Nastasi</i>	1784

	5-Fluorouracil (5-FU) intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer <i>Ph. Rougier, B. Paillet, A. LaPlanche, F. Morvan, J.F. Seitz, C. Rekeciewicz, P. Laplaige, J. Jacob, S. Grandjouan, J.M. Tignat, M.C. Fabri, M. Lubinski and M. Ducreux</i>	1789
	Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma <i>B. Ljungberg, K. Grankvist and T. Rasmuson</i>	1794
	The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma <i>E.H. Åvall-Lundqvist, C. Silfverswärd, U. Aspenblad, B.R. Nilsson and G.U. Auer</i>	1799
	Lymph node sonography versus palpation for detecting recurrent disease in patients with malignant melanoma <i>M. Binder, H. Kittler, A. Steiner, R. Dorffner, K. Wolff and H. Pehamberger</i>	1805
	Baseline quality of life of patients with advanced prostate cancer <i>D. Curran, S. Fossa, N. Aaronson, G. Kiebert, F. Keuppens and R. Hall</i>	1809
Paediatric Oncology Announcement	Paediatric Update Series	1815
	Phase II study of 21 day schedule oral etoposide in children <i>A. Davidson, R. Gowing, S. Lewis, D. Newell, I. Lewis, C. Dicks-Mireaux and C.R. Pinkerton on behalf of the New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG)</i>	1816
	Cisplatin pharmacokinetics in children with cancer <i>B. Peng, M.W. English, A.V. Boddy, L. Price, R. Wyllie, A.D.J. Pearson, M.J. Tilby and D.R. Newell</i>	1823
Epidemiology and Cancer Prevention	Incidence of second primary cancers in three Italian population-based cancer registries <i>E. Buiatti, E. Cricci, S. Acciai, L. Gafà, F. Falcini, C. Milandri and M. La Rosa</i>	1829
	Management and survival of ovarian cancer patients in South East England <i>C.D.A. Wolfe, K. Tilling and K.S. Raju</i>	1835
	Cervical cancer mortality in Belgium, 1955–1989. A descriptive study <i>S. Vyslouzilova, M. Arbyn, H. Van Oyen, S. Drieskens and P. Quataert</i>	1841
Experimental Oncology	c-erbB-3 protein expression in ductal carcinoma <i>in situ</i> of the breast <i>L.G. Bodrow, R.R. Millis, L.C. Happerfield and W.J. Gullick</i>	1846
	Frequent detection of mutations in the 5' flanking region of the prostate-specific antigen gene in female breast cancer <i>D. Tsuyuki, L. Grass and E.P. Diamandis</i>	1851

Efficacy and mechanism of aluminium phthalocyanine and its sulphonated derivatives mediated photodynamic therapy on murine tumours <i>W.-S. Chan, N. Brasseur, C. La Madeleine, R. Ouellet and J.E. van Lier</i>	1855
Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue <i>K. Sundelin, M. Jäder, L. Norberg-Spaak, Å. Davidsson and H.B. Hellquist</i>	1860
No evidence of known types of human papillomavirus in squamous cell cancer of the oesophagus in a low-risk area <i>T.C. Kok, K. Nooter, S.P. Tjong-A-Hung, H.L. Smits and J. Ter Schegget for the Rotterdam Oesophageal Tumour Study Group, Rotterdam, The Netherlands</i>	1865
An intronic germline transition in the HNPCC gene, <i>hMSH2</i> is associated with sporadic colorectal cancer <i>C. Goessl, J. Plachke, S. Pistorius, M. Hahn, S. Frank, M. Hampl, H. Görgens, R. Koch, H.-D. Saeger and H.K. Schachert</i>	1869
Expression of two 50kDa proteins is associated with sensitivity towards etherlipid analogues in the human leukaemia cell line HL 60 <i>D. Berkovic, W. Hiddemann, J. Kuduz and E.A.M. Fleer</i>	1875
Experimental antitumour activity of S 16020-2 in a panel of human tumours <i>L. Kraus-Berthier, N. Guilbaud, M. Jan, D. Saint-Dizier, M.H. Rouillon, M.F. Burbridge, A. Pierré and G. Atassi</i>	1881
Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas <i>G.E. Piérard and C. Piérard-Franchimont</i>	1888

Short Communications

Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group <i>G. Fountzilas, A. Athanassiadis, A. Kalogera-Fountzila, G. Aravantinos, D. Bafaloukos, E. Briasoulis, N. Dombros, I. Ioannidis, N. Pavlidis, P. Kosmidis and D. Skarlos</i>	1893
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer: Results of a phase II study <i>C.-H. Köhne, A. Harstick, W. Hiddemann, P. Schöffski, H. Wilke, C. Bokemeyer, B. Dörken and H.-J. Schmoll</i>	1896
Higher doses of α -interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma <i>L. Trandafir, F. Ruffié, C. Borel, I. Monnet, P. Soulié, D. Adams, E. Cvitkovic and J.P. Armand</i>	1900

Letters

Comments on <i>p53</i> protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast, Rudas <i>et al.</i> , <i>Eur. J. Cancer</i> 1997, 33 , No. 1, 39-44 (i) <i>F.C. Schmitz</i>	1903
(ii) Response from: <i>M. Rudas, R. Neumayer, M.F.X. Gnant, M. Mittelböck, R. Jakesz and A. Reiner</i>	1904

Combined effects of cisplatin and N,N-diethyl-2-[4-(Phenylmethyl)Phenoxy] Ethanamine HCl on the growth of human ovarian cancer xenografts in nude mice <i>H. Hiramatsu, K. Kudoh, Y. Kikuchi, J. Hirata, T. Kita, K. Yamamoto, T. Tode and I. Nagata</i>	1904
Paclitaxel in recurrent ovarian cancer: better upfront? Comments on: <i>a phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study, Aravatinos et al., Eur. J. Cancer, 1997, 33, 160–163</i> <i>V.R. Bulusu</i>	1905
Correction	1907
Calendar of Forthcoming Meetings	I
Information for Authors	IV

NUMBER 12

Special Issue: Advances in Neuroblastoma Research—1996

Guest editors: Garrett Brodeur and Andrew Pearson

Foreword <i>G.M. Brodeur, A.D.J. Pearson</i>	1909
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma <i>M.D. Norris, S.B. Bordow, P.S. Haber, G.M. Marshall, M. Kavallaris, J. Madafoglio, S.L. Cohn, H. Salwen, M.L. Schmidt, D.R. Hipfner, S.P.C. Cole, R.G. Deeley and M. Haber</i>	1911
Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 study <i>H. Rubie, O. Delattre, O. Hartmann, V. Combaret, J. Michon, J. Bénard, M.C. Peyroulet, D. Plantaz, C. Coze, P. Chastagner, M.C. Baranzelli, D. Frappaz, J. Lemerle and D. Sommelet, for the Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP)</i>	1917
Molecular genetic analysis of familial neuroblastoma <i>J.M. Maris, S.M. Kyemba, T.R. Rebbeck, P.S. White, E.P. Sulman, S.J. Jensen, C. Allen, J.A. Biegel and G.M. Brodeur</i>	1923
Telomerase expression in primary neuroblastomas <i>C.P. Reynolds, J.J. Zuo, N.W. Kim, H. Wang, J.N. Lukens, K.K. Matthay and R.C. Seeger</i>	1929
Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour? <i>E. Hiyama, K. Hiyama, K. Ohtsu, H. Yamaoka, T. Ichikawa, J.W. Shay and T. Yokoyama</i>	1932
Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid <i>K. David, A. Ehrhardt, M.W. Ollert, R. Erttmann, R. Bredehorst and C.-W. Vogel</i>	1937

Mechanisms of <i>in vivo</i> antineuroblastoma activity of human natural IgM <i>M.W. Ollert, K. David, C. Vollmert, H. Juhl, R. Erttmann, R. Bredehorst and C.-W. Vogel</i>	1942
Restriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus <i>DIS94</i> in neuroblastoma patients <i>P. Perri, A. Pession, K. Mazzocco, P. Scaruffi, P. Strigini, A. Iolascon, M.P. Albergoni, G. Basso and G.P. Tonini</i>	1949
Loss of heterozygosity for chromosome 1p in familial neuroblastoma <i>G.P. Tonini, C. Lo Cunsolo, R. Cusano, A. Iolascon, M. Dagnino, M. Conte, C. Milanaccio, B. De Bernardi, K. Mazzocco and P. Scaruffi</i>	1953
Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma <i>P.S. White, J.M. Maris, E.P. Sulman, S.J. Jensen, S.M. Kyemba, C.P. Beltinger, C. Allen, D.L. Kramer, J.A. Biegel and G.M. Brodeur</i>	1957
Alterations of the tumour suppressor gene <i>DCC</i> in neuroblastoma <i>X.-T. Kong, S.-H. Choi, A. Inoue, J. Takita, J. Yokota, R. Hanada, K. Yamamoto, F. Bessho, M. Yanagisawa and Y. Hayashi</i>	1962
Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma <i>K. Hallstenson, S. Thulin, H. Aburatani, Y. Hippo and T. Martinsson</i>	1966
Loss of heterozygosity in neuroblastomas—an overview <i>J. Takita, Y. Hayashi and J. Yokota</i>	1971
Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes <i>N. Van Roy, G. Laureys, M. Van Gele, G. Opdenakker, R. Miura, P. van der Drift, A. Chan, R. Versteeg and F. Speleman</i>	1974
Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis <i>M. Van Gele, N. Van Roy, A. Jauch, G. Laureys, Y. Benoit, V. Schelfhout, C.R. De Potter, P. Brock, A. Uytendaele, R. Sciot, E. Schuurings, R. Versteeg and F. Speleman</i>	1979
Prognostic relevance of genetic alterations in the p32 region of chromosome 1 in neuroblastoma <i>S. Avigad, H. Benyaminy, Y. Tamir, D. Luria, I. Yaniv, J. Stein, B. Stark and R. Zaizov</i>	1983
A product of <i>DAN</i> , a novel candidate tumour suppressor gene, is secreted into culture medium and suppresses DNA synthesis <i>Y. Nakamura, T. Ozaki, A. Nakagawara and S. Sakiyama</i>	1986
Human Krüppel-related 3 (<i>HKR3</i>): a candidate for the 1p36 neuroblastoma tumour suppressor gene? <i>J.M. Maris, J. Jensen, E.P. Sulman, C.P. Beltinger, C. Allen, J.A. Biegel, G.M. Brodeur and P.S. White</i>	1991
Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours <i>T. Martinsson, R.M. Sjöberg, K. Hallstenson, M. Nordling, F. Hedborg and P. Kogner</i>	1997
Drug resistance in human neuroblastoma cell lines correlates with clinical therapy <i>N. Keshelava, R.C. Seeger and C.P. Reynolds</i>	2002

Betulinic acid induces apoptosis in human neuroblastoma cell lines <i>M.L. Schmidt, K.L. Kuzmanoff, L. Ling-Indeck and J.M. Pezzuto</i>	2007
DNA-topoisomerase I, a new target for the treatment of neuroblastoma <i>G. Vassal, C. Pondarré, C. Cappelli, M.J. Terrier-Lacombe, I. Boland, J. Morizet, J. Bénard, A.M. Vénuat, P. Ardouin, O. Hartmann and A. Gouyette</i>	2011
Buthionine sulfoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines <i>C.P. Anderson, J. Tsai, W. Chan, C.K. Park, L. Tian, R.M. Lui, H.J. Forman and C.P. Reynolds</i>	2016
Angiostatic treatment of neuroblastoma <i>E. Wassberg and R. Christofferson</i>	2020
Detection of neuroblastoma cells in CD34 ⁺ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside G _{a2} immunocytochemistry <i>H.N. Lode, R. Handgretinger, U. Schuermann, G. Seitz, T. Klingebiel, D. Niethammer and J. Beck</i>	2024
The prognostic value of <i>MDR1</i> gene expression in primary untreated neuroblastoma <i>M. Haber, S.B. Bordow, P.S. Haber, G.M. Marshall, B.W. Stewart and M.D. Norris</i>	2031
Analysis of candidate gene co-amplification with <i>MYCN</i> in neuroblastoma <i>R.E. George, R. Kenyon, A.G. McGuckin, N. Kohl, P. Kogner, H. Christiansen, A.D.J. Pearson and J. Lunec</i>	2037
Neuroblastoma cells can actively eliminate supernumerary <i>MYCN</i> gene copies by micronucleus formation—sign of tumour cell reversion? <i>I.M. Ambros, S. Pimpler, A. Luegmayr, C.M. Hattinger, S. Strehl, H. Kovar, H. Gadner and P.F. Ambros</i>	2043
Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study <i>A. Nakagawara and G.M. Brodeur</i>	2050
Expression and function of <i>trk-C</i> in favourable human neuroblastomas <i>D.J. Yamashiro, X.-G. Liu, C.P. Lee, A. Nakagawara, N. Ikegaki, L.M. McGregor, S.B. Baylin and G. M. Brodeur</i>	2054
Coexpression of mRNA for the full-length neurotrophin receptor <i>trk-C</i> and <i>trk-A</i> in favourable neuroblastoma <i>T. Svensson, M. Rydén, F.H. Schilling, C. Dominici, R. Sehgal, C.F. Ibáñez and P. Kogner</i>	2058
Activity of a 40 kDa RNA-binding protein correlates with <i>MYCN</i> and <i>c-fos</i> mRNA stability in human neuroblastoma <i>D. Chagnovich and S.L. Cohn</i>	2064
Activation of <i>trk-A</i> but not <i>trk-B</i> signal transduction pathway inhibits growth of neuroblastoma cells <i>E. Lucarelli, D. Kaplan and C.J. Thiele</i>	2068
HuD, a neuronal-specific RNA-binding protein, is a potential regulator of <i>MYCN</i> expression in human neuroblastoma cells <i>R.A. Ross, D.L. Lazarova, G.T. Manley, P.S. Smitt, B.A. Spengler, J.B. Posner and J.L. Biedler</i>	2071

Retinoids in neuroblastoma therapy: distinct biological properties of 9- <i>cis</i> - and all- <i>trans</i> -retinoic acid <i>P.E. Lovat, H. Irving, M. Annicchiarico-Petruzzelli, F. Bernassola, A.J. Malcolm, A.D.J. Pearson, G. Melino and C.P.F. Redfern</i>	2075
Interleukin-1 β converting enzyme (ICE) is preferentially expressed in neuroblastomas with favourable prognosis <i>H. Ikeda, Y. Nakamura, T. Hiwasa, S. Sakiyama, K. Kuida, M.S.-S. Su and A. Nakagawara</i>	2081
Somatostatin in neuroblastoma and ganglioneuroma <i>P. Kogner, P. Eorgström, P. Bjellerup, F.H. Schilling, E. Refai, C. Jonsson, C. Dominici, E. Wassberg, H. Bihl, H. Jacobsson, E. Theodorsson and M. Hassan</i>	2084
Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma <i>K. Kramer, W. Gerald, L. LeSauter, H.U. Saragovi and N.-K.V. Cheung</i>	2090
The current contribution of molecular factors to risk estimation in neuroblastoma patients <i>F. Berthold, K. Şahin, B. Hero, H. Christiansen, M. Gehring, D. Harms, S. Horz, F. Lampert, M. Schwab and J. Terpe</i>	2092
Correlation of MYCN amplification, trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma <i>K. Kramer, N.-K.V. Cheung, W.L. Gerald, M. LaQuaglia, B.H. Kushner, J.-M. LeClerc, L. LeSauter and H.U. Saragovi</i>	2098
Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma <i>V. Combaret, N. Gross, C. Lasset, D. Frappaz, C. Beretta-Brogna, T. Philip, D. Beck and M.C. Favrot</i>	2101
Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children <i>W.G. Woods, M. Tuchman, L.L. Robison, M. Bernstein, J.-M. LeClerc, L.C. Brisson, J. Brossard, G. Hill, J. Shuster, R. Luepker, T. Byrne, S. Weitzman, G. Bunin, B. Lemieux and G.M. Brodeur</i>	2106
The International Neuroblastoma Risk Group (INRG): a preliminary report <i>R.P. Castleberry, J. Pritchard, P. Ambros, F. Berthold, G.M. Brodeur, V. Castel, S.L. Cohn, B. De Bernardi, C. Dicks-Mireaux, D. Frappaz, G.M. Haase, M. Haber, D.R. Jones, V.V. Joshi, M. Kaneko, J.T. Kemshead, P. Kogner, R.E.J. Lee, K.K. Matthay, J.M. Michon, R. Monclair, B.R. Roald, R.C. Seeger, P.J. Shaw, H. Shimada and J.J. Shuster</i>	2113
Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers <i>N.-K.V. Cheung, B.H. Kushner, M.P. LaQuaglia, K. Kramer, P. Ambros, I. Ambros, M. Ladanyi, J. Eddy, M.-A. Bonilla and W. Gerald</i>	2117
Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from The Pediatric Oncology Group <i>D. Strother, J. van Hoff, P.V. Rao, E.I. Smith, R.C. Shamberger, E.C. Halperin, K.J. Murray and R.P. Castleberry</i>	2121
Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by <i>in vitro</i> mafosfamide-purged autologous bone marrow transplantation <i>O. Hartman, D. Valteau-Couanet, E. Benhamou, G. Vassal, H. Rubie, F. Beaujean and J. Lemerle</i>	2126

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions <i>T. Philip, R. Ladenstein, C. Lasset, O. Hartmann, J. M. Zucker, R. Pinkerton, A.D.J. Pearson, T. Klingebiel, A. Garaventa, B. Kremens, J.L. Bernard, G. Rosti and F. Chauvin for the European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party</i>	2130
 <i>Abstracts</i>	
A constitutional balanced 1;17 neuroblastoma translocation <i>P. van der Drift, A. Chan, G. Laureys, N. van Roy, A. Westerveld, F. Speleman and R. Versteeg</i>	2136
Chromosome 1p in neuroblastoma: suppressors and prognosis <i>H. Caron, P. van Sluis, J. de Kraker, J. Böklerink, M. Egeler, G. Laureys, P.A. Voute, R. Slater, A. Westerveld and R. Versteeg</i>	2136
Genetic gains and losses in neuroblastoma <i>D. Plantaz, G. Mohapatra, K. Matthey, M. Pellarin, R. Seeger and B.G. Feuerstein</i>	2137
Targeted expression of MYCN causes neuroblastoma in transgenic mice <i>W.A. Weiss, K. Aldape, J.M. Bishop</i>	2137
Human <i>trk-B</i> promoter: isolation and characterisation reveals novel retinoic acid inducible transcription unit involving INR and 3' direct repeat element <i>Y. Kitajima, K. Matsumoto, M. Morrill and C.J. Thiele</i>	2138
Identification of a novel thyroid hormone receptor responsive element in the human <i>trk-B</i> promoter <i>C. Gaetano, Y. Kitajima, K. Matsumoto, T. Matsuo and C.J. Thiele</i>	2138
Quantitation of <i>trk-A</i> mRNA by RT-PCR identifies biologically and clinically distinct subsets of neuroblastoma <i>J. Peters, R.C. Seegar, B. Cai, D. Yao, C.M. Hong, J. Lukens, K.K. Matthay, D.O. Stram and H. Shimada</i>	2139
Genes involved in metastatic dissemination and in response to chemotherapy in the neuroblastoma IGR-N-91 model <i>J. Da Silva, N. Duarte, E. Ferrandis and J. Bénard</i>	2139
Information for Authors	IV

NUMBER 13

<i>International Cancer News</i>	2141
 <i>Editorial</i>	
Chemotherapy for metastatic breast cancer—when is enough enough? <i>M. Stockler, N. Wilcken and A. Coates</i>	2147

Current
Controversies
in Cancer

- Should prophylactic surgery be used in women with a high risk of breast cancer? 2149
Pro: J.G.M. Klijn
Contra: N. Janin
Arbiter: H. Cortés-Funes and R. Colomer

Reviews

- Basic population and cancer genetics and their use in the assessment of cancer risk 2160
G.H. Lyman and N.M. Kuderer
- Phase II trials of docetaxel (Taxotere[®]) in advanced ovarian cancer—an updated overview 2167
S.B. Kaye, M. Ficcari, M. Aapro, P. Francis and J. Kavanagh

Clinical Oncology
Updates

- Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes 2171
M. Clemons, M. Leahy, J. Valle, G. Jayson, M. Ranson, S. Hayes and A. Howell
- Review of recent trials of chemotherapy for advanced breast cancer: the taxanes 2183
M. Clemons, M. Leahy, J. Valle, G. Jayson, M. Ranson and A. Howell

Clinical Oncology

- A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast 2194
R.K. Gregory, T.J. Powles, J.C. Chang and S. Ashley
- Phase II study of semisynthetic paclitaxel in metastatic breast cancer 2198
C. Hudis, L. Riccio, F. Holmes, A. Seidman, J. Baselga, V. Currie, D. Fennelly, T. Gilewski, M. Moynahan, G. Raptis, N. Sklarin, A. Surbone, M. Uhlenhopp, N. Maickel, T.J. Yao, S. Hellman, J. Usakewicz, G. Hortobagyi and L. Norton
- Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome 2203
D. Muller, R. Millon, M. Velten, G. Bronner, G. Jung, A. Engelmann, H. Flesch, M. Eber, G. Methlin and J. Abecassis

Paediatric

- Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group 2211
T. Sahmoud, F.E. Postmus, C.H. van Pottelsberghe, K. Mattson, L. Tammilehto, T.A.W. Splinter, A.S.T. Planting, T. Sutedja, J. van Pawel, N. van Zandwijk, P. Baas, K.J. Roozendaal, M. Schrijver, A. Kirkpatrick, M. van Glabbeke, A. Ardizzoni and G. Giaccone
- Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer 2216
T. Painbenti, E. Gamelin, A. Cailleux, A. Le Bouil, M. Boisdron-Celle, A. Daver, F. Larra and P. Allain
- Clinicians' attitudes to clinical trials of cancer therapy 2221
L. Fallowfield, D. Ratcliffe and R. Souhami

Oncology
Paediatric Update

- Soft tissue sarcomas 2230
By R.B. Womer with a Commentary by M. Stevens

Epidemiology
and Cancer
Prevention

- The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study 2237
O. Bratt, U. Kristofjersson, R. Lundgren and H. Olsson
- Cancer survival from incident cases of a population-based study in the Umbria region, Italy 2241
F. La Rosa, L. Minelli, A.M. Petrinelli, G. Angeli, A.C. Epifani and V. Mastrandrea

Experimental
Oncology

- Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 β (IL-1 β), interleukin-11 (IL-11) and tumour necrosis factor- α (TNF- α) in p53-characterised human ovarian carcinomas 2246
J.G.W. Asschert, E. Vellenga, H. Hollema, A.G.J. van der Zee and E.G.E. de Vries
- Short- and long-term oestradiol treatment inhibits growth and alters expression of p21^{WAF1/Cip1} in an endometrial adenocarcinoma cell line lacking functional p53 2252
L. Karlsson, U. Delle and G. Horvath
- Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity 2258
A.B.P. Van Kuilenburg, P. Vreken, L.V.A.M. Beex, R. Meinsma, H. Van Lenthe, R.A. De Abreu and A.H. Van Gennip
- Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar–Luxembourg region are less frequent than predicted by the classic adenoma–carcinoma sequence model 2265
M. Pauly, M. Schnitz, I. Kayser, Ö. Türeci, P. Lagoda, G. Seitz and M. Dicato
- Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia 2273
A. Sebestyén, I. Kovalszky, R. Mihalik, M. Gallai, J. Bocsi, E. László, S. Benedek, L. Sréter and L. Kopper
- Immunohistochemical determination of thymidylate synthase in colorectal cancer—methodological studies 2278
D. Edler, H. Blomgren, C.J. Allegra, P.G. Johnston, U. Lagerstedt, I. Magnusson and P. Ragnhammar

Letters

- A case of brain metastases from male breast cancer responding to tamoxifen 2282
R.E.N. van Rijswijk, R.J. van Oostenbrugge and A. Twijnstra
- Co-segregation of *BRCA1* 185delAG mutation and *BRCA2* 6174delT in one single family 2283
R. Gershoni-Baruch, E. Dagan, I. Kepten and G. Freid

Is it reasonable to select the median value of T_{Pot} as a cut-off level in prediction of radiation treatment outcome?	2284
<i>R. Suwinski and H.R. Withers</i>	

*Calendar of
Forthcoming
Meetings*

I

Information for: Authors

V

NUMBER 14

<i>International Cancer News</i>	2287
--------------------------------------	------

Editorial

Breast cancer following treatment of Hodgkin's disease—more reasons for less radiotherapy?	2293
<i>J. Wolf, G. Schellong and V. Diehl</i>	

*Current
Controversies
in Cancer*

Is limb amputation necessary for locally advanced soft tissue sarcomas?	2295
<i>Pro: B. Gunterberg</i>	
<i>Contra: A.M.M. Eggermont</i>	
<i>Arbiter: W.F. Enneking</i>	

Review

Management of cutaneous melanoma M0: state of the art and trends	2302
<i>C.R. Rossi, M. Foletto, A. Vecchiato, S. Alessio, N. Menin and M. Lise</i>	

*Meeting
Highlight*

Lung cancer in the elderly	2313
<i>C. Gridelli, F. Perrone and S. Monfardini</i>	

Clinical Oncology

Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients	2315
<i>B. Cutuli, F. Dhermain, C. Borel, A. de Larochefordiere, Y. Graic, B. de Lafontan, J.M. Dilhyudy, H. Mignotte, E. Tessier, J. Tortochaux, T. N'Guyen, P. Bey, A. Le Mevel-Le Pourhiet, M. Velten and R. Arriagada</i>	

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy	2321
<i>M. Castiglione-Gertsch, M. Tattersall, A. Hacking, A. Goldhirsch, A. Gudgeon, R.D. Gelber, J. Lindtner, A. Coates, J. Collins, M. Isley, H.-J. Senn and C.-M. Rudenstam for the International Breast Cancer Study Group</i>	

	Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party <i>M. Paesmans, J.P. Sculier, P. Libert, G. Bureau, G. Dabouis, J. Thiriaux, J. Michel, O. Van Cutsem, R. Sergysels, P. Mommen and J. Klastersky for the European Lung Cancer Working Party</i>	2326
	Effect on prognosis of bone marrow infiltration detected by magnetic resonance imaging in small cell lung cancer <i>T. Seto, F. Imamura, K. Kuriyama, T. Funakoshi, H. Gotoh, T. Nakayama, S. Nakamura and T. Horai</i>	2333
	nm23 Protein expression in larynx cancer and the relationship with metastasis <i>M. Gunduz, A. Ayhan, I. Gullu, M. Onerci, A.S. Hosal, B. Gursel, I.N. Hosal and D. Firat</i>	2338
	Prognostic significance of microsatellite instability in patients with gastric carcinoma <i>J.D. Hayden, L. Cawthwell, P. Quirke, M.F. Dixon, A.R. Goldstone, H. Sue-Ling, D. Johnston and I.G. Martin</i>	2342
	The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia <i>T. Robak, M. Błasińska-Morawiec, J.Z. Błonski, E. Krykowski, M. Komarnicki, E. Trepńska, M. Kazmierczuk, J. Hansz, A. Dmoszyńska, J. Roliński, L. Konopka, A.B. Skotnicki, W.S. Nowak, S. Kotlarek-Haus, B. Zdziarska and I. Urasinski</i>	2347
	Loss of physical functioning among geriatric cancer patients: relationships to cancer site, treatment, comorbidity and age <i>M.E. Kurtz, J.C. Kurtz, M. Stommel, C.W. Given and B. Given</i>	2352
Paediatric Oncology Announcement	Paediatric Update Series	2359
	Ewing's sarcoma of the pelvis: changes over 25 years in treatment and results <i>J.M.V. Burgers*, F. Oldenburger, J. de Kraker, B.N.F.M. van Bunningen, J.W. van der Eijken, J.F.M. Delemarre, C.R. Staalman and P.A. Voûte</i>	2360
	High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by haematopoietic stem cell rescue in patients with high-risk retinoblastoma: an SFOP and SFGM study <i>F. Namouni, M. Doz, M.L. Tanguy, E. Quintana, J. Michon, H. Pacquement, E. Bouffet, J.C. Gentet, D. Flantaz, P. Lutz, J.P. Vannier, P. Validire, S. Neuenschwander, L. Desjardins and J.M. Zucker</i>	2368
Epidemiology and Cancer Prevention	Cancer in the offspring of parents with lung cancer <i>N. Seersholm, H. Hertz and J.H. Olsen</i>	2376
	Hodgkin's disease in a national and hospital population: trends over 20 years <i>A. Foss Abrahamsen, T. Egeland, St. Hansen, R. Langholm, H. Holte and S. Kvaløy</i>	2380

Experimental
Oncology

- Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells 2384
N. Sathiyamoorthy and T.T.Y. Wang
- A *BRCA1* founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing 2390
A. Dørum, P. Møller, E. J. Kamsteeg, H. Scheffer, M. Burton, K.R. Heimdal, L.O. Mæhle, E. Hovig, C.G. Tropé, A.H. van der Hout, M.A. van der Meulen, C.H.C.M. Buys and G. J. te Meerman
- Frequent allelic losses on chromosome 13q in human male breast carcinomas 2393
S. Wängren, A. van den Heuvel, M. Gentile, K. Olsen, T. Hatschek and P. Söderkvist
- Transforming growth factor β isoform expression in human ovarian tumours 2397
J.M. Bartlett, S.P. Langdon, W.W. Scott, S.B. Love, E.P. Miller, D. Katsaros, J.F. Smyth and W.R. Miller
- Preclinical activity of *trans*-indazolium [Tetrachlorobisindazoleruthenate (III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells 2404
H. Depenbrock, S. Schmelcher, R. Peter, B.K. Keppler, G. Weirich, T. Block, J. Rastetter and A.-R. Hanauske
- Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin 2411
J. Vachtenheim and H. Novotná
- A pharmacokinetic and pharmacodynamic study *in vivo* of human HT29 tumours using ^{19}F and ^{31}P magnetic resonance spectroscopy 2418
P. McSheehy, M.T. Seymour, A.S.E. Ojugo, L.M. Rodrigues, M.O. Leach, I.R. Judson and J.R. Griffiths

Short
Communications

- Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer 2428
K. Zarogoulidis, A. Papagiannis, E. Ziogas, E. Fehantidou, G. Dermizakis, D. Gioulekas and C. Vamvakis
- 'Dosimetric breast size': a new and useful parameter for the prediction of local recurrence after breast conservative treatment 2432
B. Cutuli, M. Velten, A. Karst, D. Jaeck, R. Renaud and J.F. Rodier

Letters

- Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer 2435
R. Malayeri, W. Wein and C. Zielinski
- Post-transplant EBV-associated pancreas carcinoma 2435
R. Sessler, U. Ruether, M. Hornberger and C. Bokemeyer

Impact of histamine and histamine ₂ receptor antagonists on quality of life and antitumour responses: results of a pilot trial <i>S. Milanese, L.A. Hansen, C.E. Desch, C. Honeycutt, F. Tesfaye and T.J. Smith</i>	2436
Recurrent ifosfamide-induced hyponatraemia <i>C. Kirch, B. Gachot, N. Germann, F. Blot and G. Nitenberg</i>	2438
Erratum	2440
Calendar of Forthcoming Meetings	I
Information for Authors	IBC

SUPPLEMENT 1

Introduction <i>P.E. Postmus</i>	S1
Non-small cell lung cancer: an overview of current management <i>J. Dancey and T. Le Chevalier</i>	S2
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine <i>N. Thatcher, P. Hopwood and H. Anderson</i>	S8
Combination therapy with gemcitabine in non-small cell lung cancer <i>A.M. Mosconi, L. Crinò and M. Tonato</i>	S14
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil <i>H. Burris and A.M. Storniolo</i>	S18
Metastatic bladder cancer: advances in treatment <i>W.M. Stadler, T.M. Kuzel, D. Raghavan, E. Levine, N.J. Vogelzang, B. Roth and F.A. Dorr</i>	S23
Advanced breast cancer: investigational role of gemcitabine <i>J. Carmichael and J. Walling</i>	S27
Gemcitabine in ovarian cancer: an overview of safety and efficacy <i>M. Kaufmann and G. von Minckwitz</i>	S31
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies <i>J. Nichols, F. Foss, T.M. Kuzel, C.F. LeMaistre, L. Platanius, M.J. Ratain, A. Rook, M. Saleh and G. Schwartz</i>	S34
Faculty Disclosure	I

<i>Off-label Uses of Commercial Products or Investigational Uses Not Cleared for Marketing Related to Eli Lilly and Company</i>	III
---	-----

Information for Authors	V
-------------------------	---

SUPPLEMENT 2

Chairman's introduction <i>J.G. McVie</i>	S1
A call for change in anticancer drug evaluation <i>E. Cvitkovic</i>	S3
Anticancer drug evaluation: continuing progress from existing methodology <i>W. ten Bokkel Huinink</i>	S8
The need for endpoints in anticancer drug trials that will simplify the clinical decision-making process <i>K. Redmond</i>	S11
A plea for improved use of the tools available for the evaluation of anticancer drugs <i>K. MacRae</i>	S14
Chairman's summary <i>J.G. McVie</i>	S17
Information for Authors	I

SUPPLEMENT 3

Radiation epidemiology and national dose registers <i>P. Boyle, D. Krewski, J.P. Ashmore, E. Cardis and J.M. Zielinski</i>	S1
The use of national registers of radiation exposure in occupational radiation risk assessment <i>J.M. Zielinski, D. Krewski, J.P. Ashmore and E. Cardis</i>	S3
Occupational radiation carcinogenesis (overview) <i>A.B. Miller</i>	S7
Protocol for a cohort mortality study of occupational radiation exposure based on the National Dose Registry of Canada <i>J.P. Ashmore, D. Krewski and J.M. Zielinski</i>	S10
Toward a U.S. national radiation dose registry ... and more <i>R. Goldsmith and B.G. Brooks</i>	S22
The U.K. national registry for radiation workers: design, development and first analysis <i>G.M. Kendall, C.R. Muirhead and B.H. MacGibbon</i>	S25

Occupational radiation epidemiology based on central dose registry of Japan <i>Y. Hosoda, N. Isshiki and M. Kaneko</i>	S33
Record linkage in the National Dose Registry of Canada <i>M.E. Fair</i>	S37
The design of national dose registries <i>J.P. Ashmore</i>	S44
Appendix	S48

SUPPLEMENT 4

Improving cancer survival in the next century <i>A. van Oosterom</i>	S1
New trends in the treatment of adult acute myeloid leukaemia <i>R. Willemze, S. Suciu, F. Mandelli, Th. de Witte, S. Amadori, M. Hayat, M.C. Petti, G. Solbu and R. Zittoun for the EORTC Leukaemia Cooperative Group and the GIMEMA</i>	S7
Recent advances in childhood cancer <i>H. Jürgens</i>	S15
The challenges and opportunities of cancer clinical research: EORTC perspectives <i>F. Meunier</i>	S23
Quality of life as an outcome in EORTC clinical trials <i>G.M. Kiebert</i>	S31
Economic evaluation of cancer treatment strategies <i>K. Torfs</i>	S35
Surgery for cancer in the elderly <i>I.S. Fentiman</i>	S40
Antimicrobial therapy in cancer patients: studies from the EORTC International Antimicrobial Therapy Cooperative Group <i>S.H. Zimmer</i>	S44
Fungal infections and the cancer patient <i>P. Ribaud</i>	S50
Pain control in patients with cancer <i>S. Ahmedzai</i>	S55
Anti-emesis with cancer chemotherapy <i>R. J. Gralla</i>	S63

SUPPLEMENT 5
Biological Therapy of Cancer—from Basic Research
to Clinical Application
Fourth International Symposium
11–14 June 1997

SUPPLEMENT 6

Introduction <i>M. Aapro</i>	S1
Cancer-specific quality of life questionnaires: the state of the art in Europe <i>A.M. Cull</i>	S3
New approaches to pain control in patients with cancer <i>S. Ahmedzai</i>	S8
Communication skills and psychological training in oncology <i>D. Razavi and N. Devaux</i>	S15
Information for Authors	I

SUPPLEMENT 7

Introduction The role of docetaxel in improving treatment outcomes in advanced breast cancer <i>R.D. Rubens</i>	S1
Impact of patient characteristics on treatment outcome: anthracycline resistance <i>A.U. Buzdar, L. Asmar, G.N. Hortobagyi</i>	S3
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients <i>P.M. Ravdin</i>	S8
Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? <i>K.I. Pritchard</i>	S11
Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer <i>J. Crown</i>	S15
Docetaxel in combination with doxorubicin or vinorelbine <i>V. Diéras, P. Fumoleau, S. Kalla, J.L. Misset, N. Azli, P. Poullart</i>	S20

List of Contents

Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients <i>W.W. ten Bokkel Huinink, V. Lustig, R. Dubbelman, A. Hiemstra, S. Rodenhuis</i>	S23
Prospects with docetaxel in the treatment of patients with breast cancer <i>M. Marty, J.M. Extra, P.H. Cottu, M. Espié</i>	S26
Information for Authors	I

SUPPLEMENT 8
ECCO 9—The European Cancer Conference
Hamburg 14–18 September 1997

SUPPLEMENT 9

The First European Conference on the Economics of Cancer

Adriaenssen, I.	PP 1	Ovarian cancer	Kardamakis, D.	PP 39	Radiotherapy costs
Akhan Ascioglu, S.	PP 2	Institutional structure	Koinuma, N.	PP 40	Cost of illness
Anton, A.	PP 43	Lung cancer	König, H.-H.	OP 15	Pancreatic cancer
Arbyn, M.	PP 3	Screening	Konski, A.	PP 41	Breast cancer
Arican, A.	PP 4	Lung cancer			
Aupérin, A.	PP 5	Febrile neutropenia	Lachaine, J.	OP 16	Anti-emetics
			Lapante, S.	PP 42	Leukaemia/lymphoma
Barber, J.	OP 1	Methodology	Launois, R.	OP 17	Colorectal cancer
Bercez, C.	PP 6	Institutional structure	LeCorroller, A.-G.	OP 18	Stem cell transplants
Bercez, C.	PP 59	Breast cancer	Liepa, A.	OP 19	Pancreatic cancer
Berger, K.	OP 2	Ovarian cancer			
Bethel, L.	OP 3	Ovarian cancer	Marquart-Moulin, G.	PP 44	Breast cancer
Blijham, G.	OP 4	Colorectal cancer	Marquart-Moulin, G.	OP 20	Patient preferences
Bloomfield, D.	OP 5	Prostate cancer	Mansley, E.	PP 46	Screening
Bonnema, J.	OP 6	Breast cancer	Michel, P.	PP 47	Colorectal cancer
Bordonaro, R.	PP 7	Leukaemia/lymphoma	Minshall, M.	PP 48	Lung cancer
Borras, J.	PP 8	Institutional structure			
Brown, J.	PP 10	Breast cancer	Paraponaris, A.	OP 21	Institutional structure
Brown, R.	OP 7	Breast cancer	Paraponaris, A.	PP 51	Institutional structure
Bruce, N.J.	PP 29	Leukaemia/lymphoma	Plate, S.	PP 52	Colorectal cancer
			Poulter, K.	OP 22	Lung cancer
Cangialose, B.C.	PP 11	Institutional structure	Protiere, C.	OP 23	Patient preferences
Couffignal, A.	PP 14	Serious adverse effects			
Coyle, D.	PP 15	Breast cancer	Reboul-Marty, J.	OP 24	Breast cancer
Coyle, D.	PP 16	Head and neck cancer	Rollier, P.	PP 68	Lung cancer
Crott, R.	PP 17	Febrile neutropenia	Rosendahl, I.	PP 53	Prostate cancer
			Roy, T.	PP 54	Diagnostic procedures
Donnet-Descartes, V.	PP 18	Stem cell transplants			
Doyle, J.	PP 19	Lung cancer	Sánchez de Toledo, J.	PP 55	Brain cancer
Durand-Zaleski, I.	OP 8	Colorectal cancer	Schmitt, C.	PP 56	Colorectal cancer
			Sculpher, M.	OP 25	Methodology
Earle, C.	OP 9	Radiotherapy costs	Seifeldin, R.	PP 57	Cost of illness
Evans, W.	PP 20	Breast cancer	Selke, B.	PP 58	Screening
			Small, N.	PP 60	Palliative care, pain
Fabricant, R.	PP 21	Screening	Sorensen, S.	PP 50	Breast cancer
Felder, S.	PP 22	Methodology	Stead, M.	OP 26	Colorectal cancer
Ferdjaoui, N.	OP 10	Methodology	Stroner, P.	PP 49	Lung cancer
Fortanier, C.	PP 23	Stem cell transplants			
			Malfair Taylor, S.	PP 45	Institutional structure
Gabriele, P.	PP 24	Radiotherapy costs	Malfair Taylor, S.	PP 61	Methodology
Glendenning, G.A.	PP 25	Colorectal cancer	Thompson, E.	OP 27	Breast cancer
Gralla, R.	PP 26	Lung cancer	Thoral, F.	OP 28	Prostate cancer
Grégoire, V.	PP 27	Head and neck cancer	Tonnaire, G.	OP 29	Institutional structure
Groener, M.	OP 11	Colorectal cancer	Tonnaire, G.	PP 62	Diagnostic procedures
Grunfeld, E.	OP 12	Breast cancer			
Grusenmeyer, P.	PP 28	Institutional structure	Van den Hout, W.	PP 63	Methodology
Guest, J.	PP 12	Palliative care, pain	Van Enckevort, P.	PP 65	Breast cancer
Guest, J.	PP 13	Palliative care, pain	Van Tiggelen, O.	PP 66	Methodology
Guignard, E.	PP 30	Breast cancer	Vergnenègre, A.	PP 67	Lung cancer
Gyrd-Hansen, D.	PP 31	Screening	Viens, P.	PP 9	Breast cancer
Hale, J.	OP 13	Colorectal cancer	Weber, W.	PP 69	Diagnostic procedures
Hamashima, C.	PP 32	Cost of illness	Whynes, D.	OP 30	Screening
Henry-Launois, B.	PP 33	Colorectal cancer	Wilson, L.	PP 70	Cost of illness
Hillner, B.	PP 34	Melanoma	Wolstenholme, J.	OP 31	Screening
Hutton, J.	PP 35	Breast cancer	Wolstenholme, J.	OP 32	Screening
Ilyin, N.	PP 36	Leukaemia/lymphoma	Yabroff, K.	OP 33	Prostate cancer
James, M.	OP 14	Diagnostic procedures	Zittoun, R.	PP 64	Leukaemia/lymphoma
Jiménez Monteagud, M.	PP 37	Anti-emetics			
Jones, W.	PP 38	Institutional structure			